<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gabapentin for chronic neuropathic pain in adults - Wiffen, PJ - 2017 | Cochrane Library</title> <meta content="Gabapentin for chronic neuropathic pain in adults - Wiffen, PJ - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gabapentin for chronic neuropathic pain in adults - Wiffen, PJ - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007938.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Gabapentin for chronic neuropathic pain in adults" name="citation_title"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="Andrew SC Rice" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Thomas Rudolf Tölle" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="Tudor Phillips" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="andrew.moore@omkltd.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD007938.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007938.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amines [*administration &amp; dosage, adverse effects]; Analgesics [*administration &amp; dosage, adverse effects]; Chronic Disease; Chronic Pain [*drug therapy]; Cyclohexanecarboxylic Acids [*administration &amp; dosage, adverse effects]; Diabetic Neuropathies [drug therapy]; Fibromyalgia [*drug therapy]; Gabapentin; Neuralgia [*drug therapy]; Neuralgia, Postherpetic [drug therapy]; Numbers Needed To Treat; Randomized Controlled Trials as Topic; gamma‐Aminobutyric Acid [*administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007938.pub4&amp;doi=10.1002/14651858.CD007938.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007938\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007938\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ms","pl","ta","pt","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007938.pub4",title:"Gabapentin for chronic neuropathic pain in adults",firstPublishedDate:"Jun 9, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007938.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007938.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007938.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007938.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007938.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007938.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007938.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007938.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007938.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007938.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>48362 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007938.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0099"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/appendices#CD007938-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/table_n/CD007938StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/table_n/CD007938StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gabapentin for chronic neuropathic pain in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0002">Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0003">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0004">Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0005">Andrew SC Rice</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0006">Thomas Rudolf Tölle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0007">Tudor Phillips</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information#CD007938-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information/en#CD007938-sec-0132">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007938.pub4">https://doi.org/10.1002/14651858.CD007938.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007938-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007938-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007938-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007938-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007938-abs-0011">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007938-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007938-abs-0001" lang="en"> <section id="CD007938-sec-0001"> <h3 class="title" id="CD007938-sec-0001">Background</h3> <p>Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage). This review updates a review published in 2014, and previous reviews published in 2011, 2005 and 2000. </p> </section> <section id="CD007938-sec-0002"> <h3 class="title" id="CD007938-sec-0002">Objectives</h3> <p>To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain in adults. </p> </section> <section id="CD007938-sec-0003"> <h3 class="title" id="CD007938-sec-0003">Search methods</h3> <p>For this update we searched CENTRAL), MEDLINE, and Embase for randomised controlled trials from January 2014 to January 2017. We also searched the reference lists of retrieved studies and reviews, and online clinical trials registries. </p> </section> <section id="CD007938-sec-0004"> <h3 class="title" id="CD007938-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind trials of two weeks' duration or longer, comparing gabapentin (any route of administration) with placebo or another active treatment for neuropathic pain, with participant‐reported pain assessment. </p> </section> <section id="CD007938-sec-0005"> <h3 class="title" id="CD007938-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with substantial pain relief (at least 50% pain relief over baseline or very much improved on Patient Global Impression of Change scale (PGIC)), or moderate pain relief (at least 30% pain relief over baseline or much or very much improved on PGIC). We performed a pooled analysis for any substantial or moderate benefit. Where pooled analysis was possible, we used dichotomous data to calculate risk ratio (RR) and number needed to treat for an additional beneficial outcome (NNT) or harmful outcome (NNH). We assessed the quality of the evidence using GRADE and created 'Summary of findings' tables. </p> </section> <section id="CD007938-sec-0006"> <h3 class="title" id="CD007938-sec-0006">Main results</h3> <p>We included four new studies (530 participants), and excluded three previously included studies (126 participants). In all, 37 studies provided information on 5914 participants. Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy. Study duration was typically four to 12 weeks. Not all studies reported important outcomes of interest. High risk of bias occurred mainly due to small size (especially in cross‐over studies), and handling of data after study withdrawal. </p> <p>In postherpetic neuralgia, more participants (32%) had substantial benefit (at least 50% pain relief or PGIC very much improved) with gabapentin at 1200 mg daily or greater than with placebo (17%) (RR 1.8 (95% CI 1.5 to 2.1); NNT 6.7 (5.4 to 8.7); 8 studies, 2260 participants, moderate‐quality evidence). More participants (46%) had moderate benefit (at least 30% pain relief or PGIC much or very much improved) with gabapentin at 1200 mg daily or greater than with placebo (25%) (RR 1.8 (95% CI 1.6 to 2.0); NNT 4.8 (4.1 to 6.0); 8 studies, 2260 participants, moderate‐quality evidence). </p> <p>In painful diabetic neuropathy, more participants (38%) had substantial benefit (at least 50% pain relief or PGIC very much improved) with gabapentin at 1200 mg daily or greater than with placebo (23%) (RR 1.7 (95% CI 1.4 to 2.0); NNT 6.6 (5.0 to 10); 6 studies, 1331 participants, moderate‐quality evidence). More participants (52%) had moderate benefit (at least 30% pain relief or PGIC much or very much improved) with gabapentin at 1200 mg daily or greater than with placebo (37%) (RR 1.4 (95% CI 1.3 to 1.6); NNT 6.6 (4.9 to 9.9); 7 studies, 1439 participants, moderate‐quality evidence). </p> <p>For all conditions combined, adverse event withdrawals were more common with gabapentin (11%) than with placebo (8.2%) (RR 1.4 (95% CI 1.1 to 1.7); NNH 30 (20 to 65); 22 studies, 4346 participants, high‐quality evidence). Serious adverse events were no more common with gabapentin (3.2%) than with placebo (2.8%) (RR 1.2 (95% CI 0.8 to 1.7); 19 studies, 3948 participants, moderate‐quality evidence); there were eight deaths (very low‐quality evidence). Participants experiencing at least one adverse event were more common with gabapentin (63%) than with placebo (49%) (RR 1.3 (95% CI 1.2 to 1.4); NNH 7.5 (6.1 to 9.6); 18 studies, 4279 participants, moderate‐quality evidence). Individual adverse events occurred significantly more often with gabapentin. Participants taking gabapentin experienced dizziness (19%), somnolence (14%), peripheral oedema (7%), and gait disturbance (14%). </p> </section> <section id="CD007938-sec-0007"> <h3 class="title" id="CD007938-sec-0007">Authors' conclusions</h3> <p>Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. The outcome of at least 50% pain intensity reduction is regarded as a useful outcome of treatment by patients, and the achievement of this degree of pain relief is associated with important beneficial effects on sleep interference, fatigue, and depression, as well as quality of life, function, and work. Around 3 or 4 out of 10 participants achieved this degree of pain relief with gabapentin, compared with 1 or 2 out of 10 for placebo. Over half of those treated with gabapentin will not have worthwhile pain relief but may experience adverse events. Conclusions have not changed since the previous update of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007938-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007938-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007938-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007938-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007938-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007938-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007938-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007938-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007938-abs-0012">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007938-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/ta#CD007938-abs-0010">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007938-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007938-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007938-abs-0003" lang="en"> <h3>Gabapentin for chronic neuropathic pain in adults</h3> <p><b>Bottom line</b> </p> <p>There is moderate‐quality evidence that oral gabapentin at doses of 1200 mg daily or more has an important effect on pain in some people with moderate or severe neuropathic pain after shingles or due to diabetes. </p> <p><b>Background</b> </p> <p>Neuropathic pain comes from damaged nerves. It is different from pain messages that are carried along healthy nerves from damaged tissue (for example, from a fall or cut, or arthritic knee). Neuropathic pain is often treated by different medicines (drugs) to those used for pain from damaged tissue, which we often think of as painkillers. Medicines that are sometimes used to treat depression or epilepsy can be effective in some people with neuropathic pain. One of these is gabapentin. Our definition of a good result was someone with a high level of pain relief and able to keep taking the medicine without side effects making them stop. </p> <p><b>Study characteristics</b> </p> <p>In January 2017 we searched for clinical trials in which gabapentin was used to treat neuropathic pain in adults. We found 37 studies that satisfied the inclusion criteria, randomising 5914 participants to treatment with gabapentin, placebo, or other drugs. Studies lasted 4 to 12 weeks. Most studies reported beneficial outcomes that people with neuropathic pain think are important. Results were mainly in pain after shingles and pain resulting from nerve damage in diabetes. </p> <p><b>Key results</b> </p> <p>In pain after shingles, 3 in 10 people had pain reduced by half or more with gabapentin and 2 in 10 with placebo. Pain was reduced by a third or more for 5 in 10 with gabapentin and 3 in 10 with placebo. In pain caused by diabetes, 4 in 10 people had pain reduced by half or more with gabapentin and 2 in 10 with placebo. Pain was reduced by a third or more for 5 in 10 with gabapentin and 4 in 10 with placebo. There was no reliable evidence for any other type of neuropathic pain. </p> <p>Side effects were more common with gabapentin (6 in 10) than with placebo (5 in 10). Dizziness, sleepiness, water retention, and problems with walking each occurred in about 1 in 10 people who took gabapentin. Serious side effects were uncommon, and not different between gabapentin and placebo. Slightly more people taking gabapentin stopped taking it because of side effects. </p> <p>Gabapentin is helpful for some people with chronic neuropathic pain. It is not possible to know beforehand who will benefit and who will not. Current knowledge suggests that a short trial is the best way of telling. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence was mostly of moderate quality. This means that the research provides a good indication of the likely effect. The likelihood that the effect will be substantially different is moderate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007938-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007938-sec-0099"></div> <h3 class="title" id="CD007938-sec-0100">Implications for practice</h3> <section id="CD007938-sec-0100"> <section id="CD007938-sec-0101"> <h5 class="title">For people with neuropathic pain</h5> <p>Gabapentin at a dose of 1800 to 3600 mg daily (1200 to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. The outcome of at least 50% pain intensity reduction is regarded as a useful outcome of treatment by people with chronic neuropathic pain, and the achievement of this degree of pain relief is associated with important beneficial effects on sleep interference, fatigue, and depression, as well as quality of life, function, and work. Around 3 to 4 out of 10 achieved this degree of pain relief with gabapentin, compared with 1 to 2 out of 10 for placebo. Over half of those treated with gabapentin will not have worthwhile pain relief. </p> </section> <section id="CD007938-sec-0102"> <h5 class="title">For clinicians</h5> <p>Gabapentin at a dose of 1800 to 3600 mg daily (1200 to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. No evidence regarding a dose‐response effect was available for doses above 1200 mg daily, but limited evidence suggested that doses lower than 1200 mg daily were less effective. Over half of those treated with gabapentin will not have worthwhile pain relief. </p> </section> <section id="CD007938-sec-0103"> <h5 class="title">For policy makers</h5> <p>Gabapentin at a dose of 1800 to 3600 mg daily (1200 to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. The level of efficacy found for gabapentin is consistent with the efficacy estimates for other drug therapies in these conditions. Over half of those treated with gabapentin will not have worthwhile pain relief. </p> </section> <section id="CD007938-sec-0104"> <h5 class="title">For funders</h5> <p>Gabapentin at a dose of 1800 to 3600 mg daily (1200 to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy. Evidence for other types of neuropathic pain is very limited. The outcome of at least 50% pain intensity reduction is regarded as a useful outcome of treatment by people with chronic neuropathic pain, and the achievement of this degree of pain relief is associated with important beneficial effects on sleep interference, fatigue, and depression, as well as quality of life, function, and work. Around 3 to 4 out of 10 achieved this degree of pain relief with gabapentin, compared with 1 to 2 out of 10 for placebo. Over half of those treated with gabapentin will not have worthwhile pain relief. The level of efficacy found for gabapentin is consistent with the efficacy estimates for other drug therapies in these conditions. </p> </section> </section> <h3 class="title" id="CD007938-sec-0105">Implications for research</h3> <section id="CD007938-sec-0105"> <section id="CD007938-sec-0106"> <h5 class="title">General</h5> <p>The design of studies in neuropathic pain, and the outcomes, are well understood, but as the number of people experiencing good pain relief with gabapentin over the longer term (12 weeks) is likely to be small, an enriched‐enrolment randomised‐withdrawal (EERW) design might provide the highest sensitivity to detect a signal (<a href="./references#CD007938-bbs2-0147" title="MooreRA , WiffenPJ , EcclestonC , DerryS , BaronR , BellRF , et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain2015;156(8):1382‐95. [DOI: 10.1097/j.pain.0000000000000088] ">Moore 2015c</a>). Since combination therapy for neuropathic pain has been reported to be more effective than monotherapy with any drug (<a href="./references#CD007938-bbs2-0077" title="ChaparroLE , WiffenPJ , MooreRA , GilronI . Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD008943.pub2] ">Chaparro 2012</a>), and combination therapy is common clinical practice, studies examining gabapentin in combination with an antidepressant could be of interest. Combinations with strong opioids are likely to be used less, owing to their limited efficacy and known harms. More interesting might be the combined use of gabapentin with tricyclic antidepressants, weak opioids, or tramadol, and examination of the timings and sequencing of these drugs with gabapentin. </p> <p>More research is warranted into the efficacy of gabapentin in painful neuropathic pain conditions where there is currently inadequate information. These conditions tend to be uncommon, and studies can be difficult, with few possible participants. </p> </section> <section id="CD007938-sec-0107"> <h5 class="title">Design</h5> <p>Reporting of clinically relevant outcomes using appropriate imputation for withdrawal would improve the relevance of the findings for clinical practice. The use of EERW designs for comparison with classic trial designs indicates that good quality EERW designs of long duration may be appropriate for neuropathic pain. </p> <p>Stratification by phenotype might be an interesting possibility for future studies (<a href="./references#CD007938-bbs2-0068" title="BaronR , MaierC , AttalN , BinderA , BouhassiraD , CruccuG , et al. Peripheral neuropathic pain: a mechanism‐related organizing principle based on sensory profiles. Pain2017;158(2):261‐72. [DOI: 10.1097/j.pain.0000000000000753] ">Baron 2017</a>), as well as the possibility of measuring pain scores with activity (including dynamic tactile allodynia) versus at rest or on average/worst/best over prior 24 hours. Participant‐level data might be of importance in identifying responder clusters and characteristics. </p> <p>While pain is important, other outcomes relating to function, sleep, fatigue, and quality of life are also important, and are probably closely linked (<a href="./references#CD007938-bbs2-0111" title="HoffmanDL , SadoskyA , DukesEM , AlvirJ . How do changes in pain severity levels correspond to changes in health status 3 and function in patients with painful diabetic peripheral neuropathy?. Pain2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] ">Hoffman 2010</a>). Participant‐level data could shed light on these relationships. </p> <p>The main issue, though, is not whether gabapentin is effective, but how best to use it in clinical practice to generate the best results for most people with a chronic neuropathic pain condition, in the shortest time, and at the lowest cost. New study designs have been proposed to examine this (<a href="./references#CD007938-bbs2-0136" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , WiffenP , et al. for the ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] ">Moore 2010f</a>). </p> </section> <section id="CD007938-sec-0108"> <h5 class="title">Measurement (endpoints)</h5> <p>Assessment of neuropathic pain and other symptoms should be based on dichotomous participant‐reported outcomes of proven clinical utility. </p> </section> <section id="CD007938-sec-0109"> <h5 class="title">Comparison between active treatments</h5> <p>There seems little point in comparing gabapentin directly with other treatments; the issue is what works for whom. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007938-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007938-sec-0029"></div> <div class="table" id="CD007938-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gabapentin compared with placebo for postherpetic neuralgia: efficacy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for postherpetic neuralgia: efficacy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with postherpetic neuralgia </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> gabapentin ≥ 1800 mg daily or gabapentin encarbil 1200 mg daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with gabapentin</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR and NNT</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in pain or equivalent</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 6.9 (5.5 to 9.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>2031 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMMPACT definition ‐ any substantial pain benefit</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.8 (1.5 to 2.1)</p> <p>NNT 6.7 (5.4 to 8.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>2260 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient Global Impression of Change much or very much improved</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR1.3 (1.2 to 1.5)</p> <p>NNT 9.7 (6.9 to 16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>2013 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMMPACT definition ‐ any at least moderate pain benefit</p> <p>(includes Gong 2008 at 25% pain relief)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.8 (1.6 to 2.0)</p> <p>NNT 4.8 (4.1 to 6.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>2260 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; NNT: number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup>Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD007938-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with peripheral diabetic neuropathy </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> ≥ 1800 mg daily or gabapentin encarbil 1200 mg daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with gabapentin</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR and NNT</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% pain intensity reduction</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 6.6 (5.0 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>1331 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any definition of substantial benefit (at least 50% pain intensity reduction or PGIC very much improved) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 6.6 (5.0 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>1331 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PGIC much or very much improved</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 4.9 (3.6 to 7.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>695 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any definition of moderate benefit (at least 30% pain intensity reduction or PGIC much or very much improved) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>520 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.4 (1.3 to 1.6)</p> <p>NNT 6.6 (4.9 to 9.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>1439 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; NNT: number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD007938-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with neuropathic pain </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> gabapentin 1800 mg to 3600 mg daily (gabapentin encarbil 1200 mg to 3600 mg daily) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with gabapentin</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR and NNH</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing at least one adverse event</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>630 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.3 (1.2 to 1.4)</p> <p>NNH 7.5 (6.1 to 9.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 studies</p> <p>4279 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many events. Unlikely new research would change this finding</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event withdrawals</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.4 (1.1 to 1.7)</p> <p>NNH 30 (20 to 66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 studies</p> <p>4346 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unlikely new research would change this finding</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (0.83 to 1.7)</p> <p>NNH not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 studies</p> <p>3948 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small number of events but no suggestion of difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 in max 3603 exposed</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 in max 2377 exposed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few events, relatively short duration for drug possibly taken over periods of years</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; NNH: number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007938-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007938-sec-0030"></div> <p>This is an update of a Cochrane Review titled 'Gabapentin for chronic neuropathic pain and fibromyalgia in adults', published in 2014 (<a href="./references#CD007938-bbs2-0191" title="MooreRA , WiffenPJ , DerryS , ToelleT , RiceASC . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] ">Moore 2014a</a>). The review has now been split and this update will consider only neuropathic pain. A separate updated review of gabapentin for fibromyalgia has been published (<a href="./references#CD007938-bbs2-0080" title="CooperTE , DerryS , WiffenPJ , MooreRA . Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012188.pub2] ">Cooper 2017</a>). </p> <p>Earlier versions of this review include 'Gabapentin for chronic neuropathic pain and fibromyalgia in adults' (<a href="./references#CD007938-bbs2-0190" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011a</a>), and 'Gabapentin for acute and chronic pain' (<a href="./references#CD007938-bbs2-0193" title="WiffenPJ , McQuayHJ , EdwardsJE , MooreRA . Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD005452] ">Wiffen 2005</a>). That was itself split out of a review previously published in the Cochrane Library on 'Anticonvulsant drugs for acute and chronic pain' (<a href="./references#CD007938-bbs2-0192" title="WiffenP , CollinsS , McQuayH , CarrollD , JadadA , MooreA . Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001133.pub2] ">Wiffen 2000</a>), an update of yet an older systematic review (<a href="./references#CD007938-bbs2-0123" title="McQuayH , CarrollD , JadadAR , WiffenP , MooreA . Anticonvulsant drugs for management of pain: a systematic review. BMJ1995;311(7012):1047‐52. ">McQuay 1995</a>). </p> <p>At a meeting in Oxford in early 2009 with Cochrane's Editor‐in‐Chief, it was decided to create separate chronic pain and acute pain reviews from the then current review on acute and chronic pain together (<a href="./references#CD007938-bbs2-0193" title="WiffenPJ , McQuayHJ , EdwardsJE , MooreRA . Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD005452] ">Wiffen 2005</a>). The meeting was in response to controversy in the USA over the effectiveness of gabapentin as an analgesic (<a href="./references#CD007938-bbs2-0120" title="LandefeldCS , SteinmanMA . The Neurontin legacy ‐ marketing through misinformation and manipulation. New England Journal of Medicine2009;360(2):103‐6. [DOI: 10.1056/NEJMp0808659] ">Landefeld 2009</a>), together with calls for the 2005 review to be updated with the inclusion of unpublished information made available through litigation (<a href="./references#CD007938-bbs2-0182" title="VedulaSS , BeroL , SchererRW , DickersinK . Outcome reporting in industry‐sponsored trials of gabapentin for off‐label use. New England Journal of Medicine2009;361(20):1963‐71. [DOI: 10.1056/NEJMsa0906126] ">Vedula 2009</a>). It was agreed to update the 2005 review by splitting the earlier one into two components: one review looking at the role of gabapentin in chronic neuropathic pain (including neuropathic pain of any cause, and fibromyalgia), and a second one to determine the effects of gabapentin in acute postoperative pain. Other reviews may examine gabapentin in chronic musculoskeletal pain. The unpublished data were included in the 2011 review on chronic neuropathic pain and fibromyalgia (<a href="./references#CD007938-bbs2-0190" title="MooreRA , WiffenPJ , DerryS , McQuayHJ . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD007938.pub2] ">Moore 2011a</a>), and in established acute postoperative pain (<a href="./references#CD007938-bbs2-0171" title="StraubeS , DerryS , MooreRA , WiffenPJ , McQuayHJ . Single dose oral gabapentin for established acute postoperative pain in adults. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD008183.pub2] ">Straube 2010</a>). </p> <p>This latest update is based on a template for drugs to treat neuropathic pain, using current standards for Cochrane Reviews, including assessment of the reliability of the evidence with GRADE, and based on criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD007938-bbs2-0131" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , McQuayH , ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, CochranePain , Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain‐‐establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./references#CD007938-bbs2-0140" title="MooreRA . What works for whom? Determining the efficacy and harm of treatments for pain. Pain2013;154(Supplement 1):S77‐S86. [DOI: 10.1016/j.pain.2013.03.024] ">Moore 2013a</a>; <a href="./appendices#CD007938-sec-0113">Appendix 1</a>). </p> <section id="CD007938-sec-0031"> <h3 class="title" id="CD007938-sec-0031">Description of the condition</h3> <p>Neuropathic pain is a consequence of a pathological maladaptive response of the nervous system to 'damage' from a wide variety of potential causes (<a href="./references#CD007938-bbs2-0079" title="CollocaL , LudmanT , BouhassiraD , BaronR , DickensonAH , YarnitskyD , et al. Neuropathic pain. Nature Reviews Disease Primers2017;3:17002. [DOI: 10.1038/nrdp.2017.2] ">Colloca 2017</a>). It is characterised by pain in the absence of an noxious stimulus, or where minor or moderate nociceptive stimuli evoke exaggerated levels of pain. Neuropathic pain may be spontaneous (continuous or paroxysmal) in its temporal characteristics or be evoked by sensory stimuli (dynamic mechanical allodynia where pain is evoked by light touch of the skin). </p> <p>Neuropathic pain is heterogeneous in etiology, pathophysiology, and clinical appearance. The 2011 International Association for the Study of Pain definition of neuropathic pain is "pain caused by a lesion or disease of the somatosensory system" (<a href="./references#CD007938-bbs2-0113" title="JensenTS , BaronR , HaanpääM , KalsoE , LoeserJD , RiceAS , et al. A new definition of neuropathic pain. Pain2011; Vol. 152, issue 10:2204‐5. [DOI: 10.1016/j.pain.2011.06.017] ">Jensen 2011</a>), based on a definition agreed at an earlier consensus meeting (<a href="./references#CD007938-bbs2-0175" title="TreedeRD , JensenTS , CampbellJN , CruccuG , DostrovskyJO , GriffinJW , et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology2008;70(18):1630‐5. [DOI: 10.1212/01.wnl.0000282763.29778.59] ">Treede 2008</a>). Neuropathic pain is associated with a variety of sensory loss (numbness) and sensory gain (allodynia) clinical phenomena, the exact patterns of which vary between people and disease, perhaps reflecting different pain mechanisms operating in an individual person and, therefore, potentially predictive of response to treatment (<a href="./references#CD007938-bbs2-0083" title="DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [DOI: 10.1016/j.pain.2014.08.014] ">Demant 2014</a>; <a href="./references#CD007938-bbs2-0107" title="HelfertSM , ReimerM , HöperJ , BaronR . Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics2015;97(2):135‐42. [DOI: 10.1002/cpt.19] ">Helfert 2015</a>; <a href="./references#CD007938-bbs2-0183" title="vonHehnCA , BaronR , WoolfCJ . Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron2012;73(4):638‐52. [DOI: 10.1016/j.neuron.2012.02.008] ">von Hehn 2012</a>). A new approach of subgrouping people with peripheral neuropathic pain of different etiologies according to intrinsic sensory profiles has generated three profiles that may be related to pathophysiological mechanisms and may be useful in clinical trial design to enrich the study population for treatment responders (<a href="./references#CD007938-bbs2-0068" title="BaronR , MaierC , AttalN , BinderA , BouhassiraD , CruccuG , et al. Peripheral neuropathic pain: a mechanism‐related organizing principle based on sensory profiles. Pain2017;158(2):261‐72. [DOI: 10.1097/j.pain.0000000000000753] ">Baron 2017</a>). </p> <p>Pre‐clinical research hypothesises a bewildering array of possible pain mechanisms that may operate in people with neuropathic pain, which largely reflect pathophysiological responses in both the central and peripheral nervous systems, including neuronal interactions with immune cells (<a href="./references#CD007938-bbs2-0067" title="BaronR , WasnerG , BinderA . Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology2012;11(1):19‐21. [DOI: 10.1016/S1474‐4422(11)70281‐2] ">Baron 2012</a>; <a href="./references#CD007938-bbs2-0075" title="CalvoM , DawesJM , BennettDL . The role of the immune system in the generation of neuropathic pain. Lancet Neurology2012;11(7):629‐42. [DOI: 10.1016/S1474‐4422(12)70134‐5] ">Calvo 2012</a>; <a href="./references#CD007938-bbs2-0183" title="vonHehnCA , BaronR , WoolfCJ . Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron2012;73(4):638‐52. [DOI: 10.1016/j.neuron.2012.02.008] ">von Hehn 2012</a>). Overall, the treatment gains in neuropathic pain, to even the most effective of available drugs, are modest (<a href="./references#CD007938-bbs2-0098" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology2015;14(2):162‐73. [DOI: 10.1016/S1474‐4422(14)70251‐0] ">Finnerup 2015</a>; <a href="./references#CD007938-bbs2-0141" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>), and a robust classification of neuropathic pain is not yet available (<a href="./references#CD007938-bbs2-0097" title="FinnerupNB , ScholzJ , AttalN , BaronR , HaanpääM , HanssonP , et al. Neuropathic pain needs systematic classification. European Journal of Pain2013;17(7):953‐6. [DOI: 10.1002/j.1532‐2149.2012.00282.x] ">Finnerup 2013</a>). </p> <p>Neuropathic pain is usually classified according to the cause of nerve injury. There may be many causes, but some common causes of neuropathic pain include diabetes (painful diabetic neuropathy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation (stump and phantom limb pain), neuropathic pain after surgery or trauma, stroke or spinal cord injury, trigeminal neuralgia, and HIV infection. Sometimes the cause is unknown. </p> <p>Many people with neuropathic pain conditions are significantly disabled with moderate or severe pain for many years. Chronic pain conditions comprised five of the 11 top‐ranking conditions for years lived with disability in 2010 (<a href="./references#CD007938-bbs2-0184" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163‐96. [DOI: 10.1016/S0140‐6736(12)61729‐2] ">Vos 2012</a>), and are responsible for considerable loss of quality of life and employment, and increased healthcare costs (<a href="./references#CD007938-bbs2-0191" title="MooreRA , WiffenPJ , DerryS , ToelleT , RiceASC . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] ">Moore 2014a</a>). A US study found the healthcare costs were threefold higher for people with neuropathic pain than matched control subjects (<a href="./references#CD007938-bbs2-0069" title="BergerA , DukesEM , OsterG . Clinical characteristics and economic costs of patients with painful neuropathic disorders. Journal of Pain2004;5(3):143‐9. [DOI: 10.1016/j.jpain.2003.12.004] ">Berger 2004</a>). A UK study and a German study showed a two‐ to threefold higher level of use of healthcare services in people with neuropathic pain than those without (<a href="./references#CD007938-bbs2-0071" title="BergerA , SadoskyA , DukesE , EdelsbergJ , OsterG . Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurology2012;12:8. [DOI: 10.1186/1471‐2377‐12‐8] ">Berger 2012</a>; <a href="./references#CD007938-bbs2-0070" title="BergerA , ToelleT , SadoskyA , DukesE , EdelsbergJ , OsterG . Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Practice2009;9(1):8‐17. [DOI: 10.1111/j.1533‐2500.2008.00244.x] ">Berger 2009</a>). For PHN, for example, studies demonstrate large loss of quality of life and substantial costs (<a href="./references#CD007938-bbs2-0165" title="ScottFT , JohnsonRW , Leedham‐GreenM , DaviesE , EdmundsWJ , BreuerJ . The burden of herpes zoster: a prospective population based study. Vaccine2006;24(9):1308‐14. [DOI: 10.1016/j.vaccine.2005.09.026] ">Scott 2006</a>; <a href="./references#CD007938-bbs2-0181" title="vanHoekAJ , GayN , MelegaroA , OpsteltenW , EdmundsWJ . Estimating the cost‐effectiveness of vaccination against herpes zoster in England and Wales. Vaccine2009;27(9):1454‐67. [DOI: 10.1016/j.vaccine.2008.12.024] ">Van Hoek 2009</a>). </p> <p>In systematic reviews, the overall prevalence of neuropathic pain in the general population is reported to be between 7% and 10% (<a href="./references#CD007938-bbs2-0180" title="vanHeckeO , AustinSK , KhanRA , SmithBH , TorranceN . Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain2014;155(4):654‐62. [DOI: 10.1016/j.pain.2013.11.013] ">Van Hecke 2014</a>), and about 7% in a systematic review of studies published since 2000 (<a href="./references#CD007938-bbs2-0191" title="MooreRA , WiffenPJ , DerryS , ToelleT , RiceASC . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] ">Moore 2014a</a>). In individual countries, prevalence rates have been reported as 3.3% in Austria (<a href="./references#CD007938-bbs2-0100" title="GustorffB , DornerT , LikarR , GrisoldW , LawrenceK , SchwarzF , et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica2008;52(1):132‐6. [DOI: 10.1111/j.1399‐6576.2007.01486.x] ">Gustorff 2008</a>), 6.9% in France (<a href="./references#CD007938-bbs2-0072" title="BouhassiraD , Lantéri‐MinetM , AttalN , LaurentB , TouboulC . Prevalence of chronic pain with neuropathic characteristics in the general population. Pain2008;136(3):380‐7. ">Bouhassira 2008</a>), and up to 8% in the UK (<a href="./references#CD007938-bbs2-0174" title="TorranceN , SmithBH , BennettMI , LeeAJ . The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain2006;7(4):281‐9. ">Torrance 2006</a>). Some forms of neuropathic pain, such as PDN and post‐surgical chronic pain (which is often neuropathic in origin), are increasing (<a href="./references#CD007938-bbs2-0104" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice2008;9:26. [DOI: 10.1186/1471‐2296‐9‐26] ">Hall 2008</a>). The prevalence of PHN is likely to fall if vaccination against the herpes virus becomes widespread. </p> <p>Estimates of incidence vary between individual studies for particular origins of neuropathic pain, often because of small numbers of cases. In primary care in the UK, between 2002 and 2005, the incidences (per 100,000 person‐years' observation) were 28 (95% confidence interval (CI), 27 to 30) for PHN, 27 (95% CI, 26 to 29) for trigeminal neuralgia, 0.8 (95% CI, 0.6 to 1.1) for phantom limb pain, and 21 (95% CI, 20 to 22) for PDN (<a href="./references#CD007938-bbs2-0104" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice2008;9:26. [DOI: 10.1186/1471‐2296‐9‐26] ">Hall 2008</a>). Other studies have estimated an incidence of 4 in 100,000 per year for trigeminal neuralgia (<a href="./references#CD007938-bbs2-0116" title="KatusicS , WilliamsDB , BeardCM , BergstralhEJ , KurlandLT . Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945‐1984. Neuroepidemiology1991;10(5‐6):276‐81. [DOI: 10.1159/000110284] ">Katusic 1991</a>; <a href="./references#CD007938-bbs2-0159" title="RappaportZH , DevorM . Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain1994;56(2):127‐38. [DOI: 10.1016/0304‐3959(94)90086‐8] ">Rappaport 1994</a>), and 12.6 per 100,000 person‐years for trigeminal neuralgia and 3.9 per 100,000 person‐years for PHN in a study of facial pain in the Netherlands (<a href="./references#CD007938-bbs2-0118" title="KoopmanJS , DielemanJP , HuygenFJ , deMosM , MartinCG , SturkenboomMC . Incidence of facial pain in the general population. Pain2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] ">Koopman 2009</a>). One systematic review of chronic pain demonstrated that some neuropathic pain conditions, such as PDN, can be more common than other neuropathic pain conditions, with prevalence rates up to 400 per 100,000 person‐years (<a href="./references#CD007938-bbs2-0126" title="McQuayHJ , SmithLA , MooreRA . Chronic Pain. In: StevensA , RafteryJ , MantJ , SimpsonS editor(s). Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews: Third Series. Oxford: Radcliffe Publishing, 2007. [ISBN: 978‐1‐84619‐063‐6] ">McQuay 2007</a>). It is also the case that pains not classified as neuropathic can have neuropathic features. In a community study of recent joint pain, features of neuropathic pain were common and were present in over half of those reporting pain of at least moderate severity (<a href="./references#CD007938-bbs2-0168" title="SoniA , BatraR , GwilymS , SpectorT , HartD , ArdenN , et al. Neuropathic features of joint pain: a community‐based study. Arthritis &amp; Rheumatism2013;April 1:Epub ahead of print. [DOI: 10.1002/art.37962] ">Soni 2013</a>). </p> <p>Neuropathic pain is difficult to treat effectively, with only a minority of people experiencing a clinically relevant benefit from any one intervention (<a href="./references#CD007938-bbs2-0115" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339. [DOI: 10.1136/bmj.f7339] ">Kalso 2013</a>; <a href="./references#CD007938-bbs2-0141" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>). A multidisciplinary approach is now advocated, combining pharmacological interventions with physical or cognitive (or both) interventions. The evidence for more invasive interventional therapies such as neural blockade or intrathecal medication is very weak, or non‐existent (<a href="./references#CD007938-bbs2-0089" title="DworkinRH , O'ConnorAB , KentJ , MackeySC , RajaSN , StaceyBR , et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain2013;154(11):2249‐61. [DOI: 10.1016/j.pain.2013.06.004] ">Dworkin 2013</a>). Conventional analgesics such as paracetamol (acetaminophen) and nonsteroidal anti‐inflammatory drugs (NSAID) are not thought to be effective, but without evidence to support or refute that view (<a href="./references#CD007938-bbs2-0145" title="MooreRA , ChiCC , WiffenPJ , DerryS , RiceASC . Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD010902.pub2] ">Moore 2015a</a>; <a href="./references#CD007938-bbs2-0189" title="WiffenPJ , KnaggsR , DerryS , ColeP , PhillipsT , MooreRA . Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012227.pub2] ">Wiffen 2016</a>). Some people may derive some benefit from a topical lidocaine patch or low‐concentration topical capsaicin, although evidence about benefits is uncertain (<a href="./references#CD007938-bbs2-0084" title="DerryS , MooreRA . Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD010111] ">Derry 2012</a>; <a href="./references#CD007938-bbs2-0085" title="DerryS , WiffenPJ , MooreRA , QuinlanJ . Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2] ">Derry 2014</a>). High‐concentration topical capsaicin may benefit some people with PHN (<a href="./references#CD007938-bbs2-0087" title="DerryS , RiceASC , ColeP , TanT , MooreRA . Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD007393.pub4] ">Derry 2017</a>). Treatment is often by so‐called 'unconventional analgesics' (pain modulators) such as antidepressants (duloxetine and amitriptyline; <a href="./references#CD007938-bbs2-0122" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] ">Lunn 2014</a>; <a href="./references#CD007938-bbs2-0143" title="MooreRA , CaiN , SkljarevskiV , TölleTR . Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain2014;18(1):67‐75. [DOI: 10.1002/j.1532‐2149.2013.00341.x] ">Moore 2014b</a>; <a href="./references#CD007938-bbs2-0146" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD008242.pub3] ">Moore 2015b</a>; <a href="./references#CD007938-bbs2-0172" title="SultanA , GaskellH , DerryS , MooreRA . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology2008;8:29. [DOI: 10.1186/1471‐2377‐8‐29] ">Sultan 2008</a>), or antiepileptics (gabapentin or pregabalin; <a href="./references#CD007938-bbs2-0130" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076] ">Moore 2009</a>; <a href="./references#CD007938-bbs2-0143" title="MooreRA , CaiN , SkljarevskiV , TölleTR . Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain2014;18(1):67‐75. [DOI: 10.1002/j.1532‐2149.2013.00341.x] ">Moore 2014b</a>; <a href="./references#CD007938-bbs2-0187" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] ">Wiffen 2013</a>). Evidence for efficacy of opioids is unconvincing (<a href="./references#CD007938-bbs2-0086" title="DerryS , StannardC , ColeP , WiffenPJ , KnaggsR , AldingtonD , et al. Fentanyl for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011605.pub2] ">Derry 2016</a>; <a href="./references#CD007938-bbs2-0099" title="GaskellH , DerryS , StannardC , MooreRA . Oxycodone for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD010692.pub3] ">Gaskell 2016</a>; <a href="./references#CD007938-bbs2-0169" title="StannardC , GaskellH , DerryS , AldingtonD , ColeP , CooperTE , et al. Hydromorphone for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD011604.pub2] ">Stannard 2016</a>; <a href="./references#CD007938-bbs2-0188" title="WiffenPJ , DerryS , MooreRA , StannardC , AldingtonD , ColeP , et al. Buprenorphine for neuropathic pain in adults. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011603.pub2] ">Wiffen 2015</a>). </p> <p>The proportion of people who achieve worthwhile pain relief (typically at least 50% pain intensity reduction; <a href="./references#CD007938-bbs2-0144" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014c</a>) is small, generally only 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNT) usually between 4 and 10 (<a href="./references#CD007938-bbs2-0115" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339. [DOI: 10.1136/bmj.f7339] ">Kalso 2013</a>; <a href="./references#CD007938-bbs2-0141" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>). Neuropathic pain is not particularly different from other chronic pain conditions in that only a small proportion of trial participants have a good response to treatment (<a href="./references#CD007938-bbs2-0141" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>). </p> <p>The current National Institute for Health and Care Excellence (NICE) guidance for the pharmacological management of neuropathic pain suggests offering a choice of amitriptyline (<a href="./references#CD007938-bbs2-0139" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] ">Moore 2012b</a>), duloxetine (<a href="./references#CD007938-bbs2-0122" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] ">Lunn 2014</a>), gabapentin, or pregabalin (<a href="./references#CD007938-bbs2-0130" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076] ">Moore 2009</a>) as initial treatment for neuropathic pain (with the exception of trigeminal neuralgia), with switching if the first, second, or third drugs tried are not effective or not tolerated (<a href="./references#CD007938-bbs2-0150" title="National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 13 February 2017). ">NICE 2013</a>). This concurs with other recent guidance (<a href="./references#CD007938-bbs2-0098" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology2015;14(2):162‐73. [DOI: 10.1016/S1474‐4422(14)70251‐0] ">Finnerup 2015</a>). </p> </section> <section id="CD007938-sec-0032"> <h3 class="title" id="CD007938-sec-0032">Description of the intervention</h3> <p>Gabapentin is licensed for the treatment of peripheral and central neuropathic pain in adults in the UK at doses up to 3.6 grams (3600 mg) daily. It is given orally, usually as tablets or capsules, but sometimes as an oral solution (50 mg/ml). Guidance suggests that gabapentin treatment can be started at a dose of 300 mg per day for treating neuropathic pain. Based on individual patient response and tolerability, the dosage may be increased by 300 mg per day until pain relief is experienced or adverse effects make taking the drug intolerable (<a href="./references#CD007938-bbs2-0091" title="Electronic Medicines Compendium. emc.medicines.org.uk/ (accessed 13 February 2017). ">EMC 2017</a>). US marketing approval for gabapentin was granted in 2002 for postherpetic neuralgia; in Europe, the label was changed to include peripheral neuropathic pain in 2006. Gabapentin has the trade name Neurontin<sup>TM</sup>, and is also available as generic products in some parts of the world. </p> <p>Gabapentin has a half‐life of five to seven hours. It is absorbed through a saturable transport system, so that absorption is not linear, and the transporter is found only in the proximal small bowel. This means that the drug needs to be administered at least three times daily, and may result in plasma trough levels. Two new formulations have attempted to improve the availability of the drug. The first is an extended release, gastro‐retentive formulation, designed to provide continuous delivery at the optimal site of absorption over 8 to 10 hours (<a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>). The second uses an extended‐release prodrug (gabapentin encarbil) that is absorbed through a high capacity transport system found throughout the intestine, and then undergoes rapid hydrolysis to gabapentin. It is claimed to provide sustained, dose‐proportional gabapentin exposure (<a href="./references#CD007938-bbs2-0003" title="BackonjaMM , CanafaxDM , CundyKC . Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Medicine2011;12(7):1098‐108. [DOI: 10.1111/j.1526‐4637.2011.01139.x] ">Backonja 2011</a>), and can be administered twice daily. </p> <p>Gabapentin can also be formulated as an aqueous solution for injection. This formulation is not available commercially or licensed for treatment of any type of neuropathic pain or fibromyalgia. </p> <p>Gabapentin misuse has been reported, and the consequences documented and systematically reviewed (<a href="./references#CD007938-bbs2-0094" title="EvoyKE , MorrisonMD , SakladSR . Abuse and misuse of pregabalin and gabapentin. Drugs2017;77(4):403‐26. [DOI: 10.1007/s40265‐017‐0700‐x] ">Evoy 2017</a>; <a href="./references#CD007938-bbs2-0158" title="QuinteroGC . Review about gabapentin misuse, interactions, contraindications and side effects. Journal of Experimental Pharmacology2017;9:13‐21. [10.2147/JEP.S124391. eCollection 2017] ">Quintero 2017</a>). </p> </section> <section id="CD007938-sec-0033"> <h3 class="title" id="CD007938-sec-0033">How the intervention might work</h3> <p>Gabapentin's mechanism of action is primarily attributed to its effect on calcium channels located throughout the peripheral and central nervous systems, which modify the release of neurotransmitters and reduce excitability of nerve cells (<a href="./references#CD007938-bbs2-0073" title="BoyleY , FernandoD , KurzH , MillerSR , ZucchettoM , StoreyJ . The effect of a combination of gabapentin and donepezil in an experimental pain model in health volunteers: results of a randomised controlled trial. Pain2014;155(12):2510‐6. [DOI: 10.1016/j.pain.2014.09.003] ">Boyle 2014</a>; <a href="./references#CD007938-bbs2-0076" title="ChangCY , ChallaCK , ShahJ , EloyJD . Gabapentin in acute postoperative pain management. Biomed Research International2014;2014:631756. [DOI: 10.1155/2014/631756] ">Chang 2014</a>). This mode of action confers antiepileptic, analgesic, and sedative effects. Research also indicates that gabapentin acts by blocking new synapse formation (<a href="./references#CD007938-bbs2-0093" title="ErogluC , AllenNJ , SusmanMW , O'RourkeNA , ParkCY , OzkanE , et al. Gabapentin receptor alpha2delta‐1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell2009;139(2):380‐92. [DOI: 10.1016/j.cell.2009.09.025] ">Eroglu 2009</a>). </p> </section> <section id="CD007938-sec-0034"> <h3 class="title" id="CD007938-sec-0034">Why it is important to do this review</h3> <p>Some, but not all, antiepileptics can reduce neuropathic pain (<a href="./references#CD007938-bbs2-0186" title="WiffenPJ , CollinsS , McQuayHJ , CarrollD , JadadA , MooreRA . Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3] ">Wiffen 2010</a>). Gabapentin is an antiepileptic widely prescribed for neuropathic pain, and it is common practice in some countries to aim for the maximum tolerated dose. There is growing controversy over whether this practice is justified by experimental evidence from double‐blind randomised trials. Guidance on prescribing typically puts gabapentin amongst the first‐line agents (<a href="./references#CD007938-bbs2-0098" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology2015;14(2):162‐73. [DOI: 10.1016/S1474‐4422(14)70251‐0] ">Finnerup 2015</a>; <a href="./references#CD007938-bbs2-0150" title="National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 13 February 2017). ">NICE 2013</a>). Despite this guidance based on good evidence, prescribing for neuropathic pain often involves paracetamol or paracetamol combined with opioids (<a href="./references#CD007938-bbs2-0105" title="HallGC , MorantSV , CarrollD , GabrielZL , McQuayHJ . An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice2013;14:28. [DOI: 10.1186/1471‐2296‐14‐28] ">Hall 2013</a>), for which there is no evidence of efficacy (<a href="./references#CD007938-bbs2-0189" title="WiffenPJ , KnaggsR , DerryS , ColeP , PhillipsT , MooreRA . Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012227.pub2] ">Wiffen 2016</a>). </p> <p>The standards used to assess evidence in chronic pain trials have evolved substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy (<a href="./appendices#CD007938-sec-0113">Appendix 1</a>). The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of 8 to 12 weeks' duration or longer. Pain intensity reduction of 50% or more correlates with improvements in co‐morbid symptoms, function, and quality of life. These standards are set out in the <i>PaPaS Author and Referee Guidance</i> for pain studies of Cochrane Pain, Palliative and Supportive Care (<a href="./references#CD007938-bbs2-0153" title="CochranePain , Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. papas.cochrane.org/papas‐documents (accessed 7 February 2017). ">PaPaS 2012</a>). </p> <p>This Cochrane Review assesses the evidence using methods that make both statistical and clinical sense, and uses developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD007938-bbs2-0131" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , McQuayH , ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, CochranePain , Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain‐‐establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] '>Moore 2010a</a>). Trials included and analysed meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc), and size (ideally at least 500 participants in a comparison in which the NNT is 4 or above; <a href="./references#CD007938-bbs2-0128" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). This approach sets high standards for the demonstration of efficacy and marks a departure from how reviews were conducted previously. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007938-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007938-sec-0035"></div> <p>To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007938-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007938-sec-0036"></div> <section id="CD007938-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007938-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with double‐blind (participant and observers) assessment of participant‐reported outcomes, following two weeks of treatment or longer, although the emphasis of the review was on studies of eight weeks or longer. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. </p> <p>We did not include short abstracts (usually meeting reports with inadequate or no reporting of data). We excluded studies of experimental pain, case reports, and clinical observations. </p> </section> <section id="CD007938-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adult participants aged 18 years and above, with one or more chronic neuropathic pain condition including (but not limited to): </p> <p> <ol id="CD007938-list-0001"> <li> <p>cancer‐related neuropathy;</p> </li> <li> <p>central neuropathic pain;</p> </li> <li> <p>complex regional pain syndrome (CRPS) Type II;</p> </li> <li> <p>HIV neuropathy;</p> </li> <li> <p>painful diabetic neuropathy;</p> </li> <li> <p>phantom limb pain;</p> </li> <li> <p>postherpetic neuralgia;</p> </li> <li> <p>postoperative or traumatic neuropathic pain;</p> </li> <li> <p>spinal cord injury;</p> </li> <li> <p>trigeminal neuralgia.</p> </li> </ol> </p> <p>Where we included studies with more than one type of neuropathic pain, we analysed results according to the primary condition if identifiable. </p> </section> <section id="CD007938-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Gabapentin in any dose, by any route, administered for the relief of neuropathic pain and compared to placebo or any other active comparator. </p> </section> <section id="CD007938-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with most studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity or pain relief, or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD007938-bbs2-0088" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). These were defined as: </p> <p> <ol id="CD007938-list-0002"> <li> <p>at least 30% pain relief over baseline (moderate);</p> </li> <li> <p>at least 50% pain relief over baseline (substantial);</p> </li> <li> <p>much or very much improved on Patient Global Impression of Change scale (PGIC; moderate);</p> </li> <li> <p>very much improved on PGIC (substantial).</p> </li> </ol> </p> <p>These outcomes concentrate on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50% pain intensity reduction, and ideally having no worse than mild pain (<a href="./references#CD007938-bbs2-0142" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013c</a>; <a href="./references#CD007938-bbs2-0152" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient‐centered perspective on treatment: outcomes in chronic pain. Pain Medicine2010;11:6‐15. [DOI: 10.1111/j.1526‐4637.2009.00685.x] ">O'Brien 2010</a>). </p> <section id="CD007938-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007938-list-0003"> <li> <p>Participant‐reported pain intensity reduction of 30% or greater</p> </li> <li> <p>Participant‐reported pain intensity reduction of 50% or greater</p> </li> <li> <p>Patient‐reported global impression of clinical change (PGIC) much or very much improved</p> </li> <li> <p>Patient‐reported global impression of clinical change (PGIC) very much improved</p> </li> </ol> </p> </section> <section id="CD007938-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007938-list-0004"> <li> <p>Any pain‐related outcome indicating some improvement.</p> </li> <li> <p>Withdrawals due to lack of efficacy, adverse events, and for any cause.</p> </li> <li> <p>Participants experiencing any adverse event.</p> </li> <li> <p>Participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the patient, or may require an intervention to prevent one of the above characteristics or consequences. </p> </li> <li> <p>Specific adverse events, particularly somnolence and dizziness.</p> </li> </ol> </p> </section> </section> </section> <section id="CD007938-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007938-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For this update we searched the following databases, without language restrictions:</p> <p> <ol id="CD007938-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), 1 January 2014 to 16 January 2017; </p> </li> <li> <p>MEDLINE via Ovid, 1 January 2014 to 16 January 2017;</p> </li> <li> <p>Embase via Ovid, 1 January 2014 to 16 January 2017.</p> </li> </ol> </p> <p>See <a href="./appendices#CD007938-sec-0114">Appendix 2</a> for the CENTRAL search strategy, <a href="./appendices#CD007938-sec-0115">Appendix 3</a> for the MEDLINE search strategy, and <a href="./appendices#CD007938-sec-0116">Appendix 4</a> for the Embase search strategy. </p> </section> <section id="CD007938-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of any RCTs identified and review articles, and searched clinical trial databases (ClinicalTrials.gov (<a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>) and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>)) to identify additional published or unpublished data. We did not contact investigators or study sponsors. </p> </section> </section> <section id="CD007938-sec-0047"> <h3 class="title" id="CD007938-sec-0047">Data collection and analysis</h3> <p>We performed separate efficacy analyses according to particular neuropathic pain conditions, and combined different neuropathic pain conditions in analyses for adverse events and withdrawals only. </p> <section id="CD007938-sec-0048"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and we obtained full copies of the remaining studies. Two review authors made the decisions. Two review authors (RAM, SD) then read these studies independently and reached agreement by discussion. We did not anonymise the studies in any way before assessment. We have provided a PRISMA flow chart to illustrate the flow of studies (Moher 2009) (<a href="#CD007938-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007938-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD007938-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD007938-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (RAM, PW, SD) extracted data independently, using a standard data extraction form, and agreed data before entry into Review Manager (RevMan) 5 (<a href="./references#CD007938-bbs2-0161" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) or any other analysis method. We included information about the pain condition and number of participants treated, drug and dosing regimen, study design, study duration and follow‐up, analgesic outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event, particular adverse events, or a serious adverse event). </p> </section> <section id="CD007938-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD007938-bbs2-0112" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJM , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. [DOI: 10.1016/0197‐2456(95)00134‐4] ">Jadad 1996</a>), limiting inclusion to studies that were randomised and double‐blind as a minimum. </p> <p>Two review authors (SD, PW) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8, <a href="./references#CD007938-bbs2-0110" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Higgins 2011</a>), and adapted from those used by Cochrane Pregnancy and Childbirth, with any disagreements resolved by discussion. We assessed the following for each study: </p> <p> <ol id="CD007938-list-0006"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process: random number table or computer random‐number generator); unclear risk of bias (when the method used to generate the sequence was not clearly stated). We excluded studies at a high risk of bias that used a non‐random process (odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively‐numbered, sealed, opaque envelopes); unclear risk of bias (when method not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias), and blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study personnel and participants (all outcomes were self‐assessed) from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, for example, identical tablets, matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies at a high risk of bias that were not double‐blind. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (fewer than 10% of participants did not complete the study or used 'baseline observation carried forward' (BOCF) analysis, or both); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); or high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size (<a href="./references#CD007938-bbs2-0081" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartres 2013</a>; <a href="./references#CD007938-bbs2-0082" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD007938-bbs2-0128" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD007938-bbs2-0151" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>; <a href="./references#CD007938-bbs2-0173" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>)). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ol> </p> </section> <section id="CD007938-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the number needed to treat for an additional beneficial outcome (NNT) as the reciprocal of the absolute risk reduction (ARR) (<a href="./references#CD007938-bbs2-0125" title="McQuayH , MooreR . An evidence‐based resource for pain relief. An evidence‐based resource for pain relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2] ">McQuay 1998</a>). For unwanted effects, the NNT becomes the number needed to treat for an additional harmful outcome (NNH) and was calculated in the same manner. We used dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixed‐effect model unless significant statistical heterogeneity was found (see below). We did not use continuous data in analyses. </p> </section> <section id="CD007938-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. For cross‐over studies we planned to use first period data where possible, but otherwise to use available data and consider any potential bias that this study design presented. </p> </section> <section id="CD007938-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post‐baseline assessment. We assigned zero improvement (baseline observation carried forward (BOCF)) to missing participants wherever possible. </p> <p>We paid particular attention to methods used for imputation of missing data due to withdrawals for adverse events and lack of efficacy. </p> </section> <section id="CD007938-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We dealt with clinical heterogeneity by combining studies that examined similar conditions. We assessed statistical heterogeneity visually (<a href="./references#CD007938-bbs2-0119" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107(2):224‐33. [DOI: 10.7326/0003‐4819‐107‐2‐224] ">L'Abbé 1987</a>) and with the use of the I<sup>2</sup> statistic (<a href="./references#CD007938-bbs2-0109" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). When the I² value was greater than 50%, we considered possible reasons for this. </p> </section> <section id="CD007938-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous outcomes of known utility and of value to people with neuropathic pain (<a href="./references#CD007938-bbs2-0111" title="HoffmanDL , SadoskyA , DukesEM , AlvirJ . How do changes in pain severity levels correspond to changes in health status 3 and function in patients with painful diabetic peripheral neuropathy?. Pain2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] ">Hoffman 2010</a>; <a href="./references#CD007938-bbs2-0131" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , McQuayH , ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, CochranePain , Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain‐‐establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./references#CD007938-bbs2-0132" title="MooreRA , StraubeS , DerryS , McQuayHJ . Topical review: chronic low back pain analgesic studies ‐ a methodological minefield. Pain2010;149(3):431‐4. [DOI: 10.1016/j.pain.2010.02.032] ">Moore 2010b</a>; <a href="./references#CD007938-bbs2-0133" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010c</a>; <a href="./references#CD007938-bbs2-0144" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014c</a>). The review did not depend on what the authors of the original studies chose to report or not, and studies that did not report dichotomous results for an outcome did not contribute to pooled analyses for that outcome. We extracted and used continuous data, which probably reflect efficacy and utility poorly, for illustrative purposes only. </p> <p>We assessed publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean a NNT of 10 or higher in this condition; <a href="./references#CD007938-bbs2-0129" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). </p> <p>We looked for effects of possible enrichment, either complete or partial, in enrolment of participants into the studies. Enrichment typically means including participants known to respond to a therapy, and excluding those known not to respond, or to suffer unacceptable adverse effects, though for gabapentin no significant effects have been shown from partial enrichment (<a href="./references#CD007938-bbs2-0170" title="StraubeS , DerryS , McQuayHJ , MooreRA . Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology2008;66(2):266‐75. [DOI: 10.1111/j.1365‐2125.2008.03200.x] ">Straube 2008</a>). Enriched enrolment randomised withdrawal studies, known to produce higher estimates of efficacy, would not be pooled (<a href="./references#CD007938-bbs2-0127" title="McQuayHJ , DerryS , MooreRA , PoulainP , LegoutV . Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain2008;135(3):217‐220. [DOI: 10.1016/j.pain.2008.01.014] ">McQuay 2008</a>). </p> </section> <section id="CD007938-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model for meta‐analysis, unless there was significant clinical heterogeneity and it was still considered appropriate to combine studies. In such cases we would use a random‐effects model. </p> <section id="CD007938-sec-0057"> <h5 class="title">Quality of evidence</h5> <section id="CD007938-sec-0058"> <h6 class="title">Quality of the evidence</h6> <p>We used the GRADE system to assess the quality of the evidence related to the key outcomes listed in <a href="#CD007938-sec-0041">Types of outcome measures</a>, as appropriate (<a href="./appendices#CD007938-sec-0118">Appendix 6</a>). Two review authors (RAM, SD) independently rated the quality of the evidence for each outcome. </p> <p>We paid particular attention to inconsistency, where point estimates varied widely across studies or confidence intervals (CIs) of studies showed minimal or no overlap (<a href="./references#CD007938-bbs2-0101" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Cinical Epidemiology2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] ">Guyatt 2011</a>), and potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD007938-bbs2-0129" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). </p> <p>In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD007938-bbs2-0102" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66:151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] ">Guyatt 2013a</a>). For example, where there were so few data that the results were highly susceptible to the random play of chance, or if a study used last observation carried forward (LOCF) imputation in circumstances where there were substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we would have reported the level of evidence as very low quality (<a href="./references#CD007938-bbs2-0103" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66:158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] ">Guyatt 2013b</a>). </p> <p>In addition, we are aware that many Cochrane Reviews are based largely or wholly on small underpowered studies, and the danger of making conclusive assessments of evidence based on inadequate information (<a href="./references#CD007938-bbs2-0066" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. International Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD007938-bbs2-0074" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD007938-bbs2-0162" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD007938-bbs2-0176" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane Reviews. PLoS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). </p> </section> <section id="CD007938-sec-0059"> <h6 class="title">'Summary of findings' table</h6> <p>We have included a 'Summary of findings' table as set out in the PaPaS author guide (<a href="./references#CD007938-bbs2-0153" title="CochranePain , Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. papas.cochrane.org/papas‐documents (accessed 7 February 2017). ">PaPaS 2012</a>), and recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 11, <a href="./references#CD007938-bbs2-0163" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>). The table includes, where possible, outcomes equivalent to moderate or substantial benefit of at least 30% and at least 50% pain intensity reduction, PGIC (possibly at least substantial improvement and at least moderate improvement) (<a href="./references#CD007938-bbs2-0088" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>), withdrawals due to lack of efficacy, withdrawals due to adverse events, serious adverse events, and death (a particular serious adverse event). </p> <p>For the 'Summary of findings' table we used the following descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>): </p> <p><b>High:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low. </p> <p><b>Moderate:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate. </p> <p><b>Low:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high. </p> <p><b>Very low:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </section> </section> </section> <section id="CD007938-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned for all analyses to be according to individual painful condition, because placebo response rates with the same outcome can vary between conditions, as can the drug‐specific effects (<a href="./references#CD007938-bbs2-0130" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076] ">Moore 2009</a>). We also planned subgroup analysis according to dose of gabapentin, and duration of study if sufficient data were available. </p> </section> <section id="CD007938-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>In the 2014 review we considered a sensitivity analysis for formulation of gabapentin (standard, gastroretentive, slow‐release), but there were insufficient data for meaningful analysis, and there were no additional data for these formulations. We planned no other sensitivity analyses because the evidence base was known to be too small to allow reliable analysis. Performing analyses that might inform on which patients were most likely to benefit from gabapentin treatment would require efficacy data together with detailed assessment of the exact nature and type of neuropathic pain at the individual participant level (<a href="./references#CD007938-bbs2-0179" title="TölleTR , BackonjaM . Pharmacological Therapy for Neuropathic Pain. In: McMahonSB , KoltenburgM , TraceyI , TurkDC editor(s). Wall and Melzack's Textbook of Pain. 5. Philadelphia: Elsevier, 2013:1003‐1011. [ISBN 978‐0‐7020‐4059‐7] ">Tölle 2013</a>). No such data were expected to be available. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007938-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007938-sec-0062"></div> <section id="CD007938-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD007938-sec-0064"> <h4 class="title">Results of the search</h4> <p>In the previous version of this review we considered 36 studies in 37 reports examining oral gabapentin, involving 5483 participants with chronic neuropathic pain in various different conditions, mainly PHN, PDN, or mixed neuropathic pain. </p> <p>Updated database searches from January 2014 to 17 January 2017 identified 107 potentially relevant reports in CENTRAL, 237 in MEDLINE, and 484 in Embase. No additional studies were identified in clinical trials registries or reference lists of included studies or reviews. </p> <p>After de‐duplication and screening of titles and abstracts, we obtained the full text of seven reports. Of these, we included three new studies, with 468 participants (<a href="./references#CD007938-bbs2-0001" title="AtkinsonJH , SlaterMA , CapparelliEV , PatelSM , WolfsonT , GamstA , et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain2016;157(7):1499‐507. [DOI: 10.1097/j.pain.0000000000000554] ">Atkinson 2016</a>; <a href="./references#CD007938-bbs2-0007" title="CohenSP , HanlingS , BicketMC , WhiteRL , VeiziE , KuriharaC , et al. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. BMJ2015;350:h1748. [CTG: NCT01495923; DOI: 10.1136/bmj.h1748] ">Cohen 2015</a>; <a href="./references#CD007938-bbs2-0012" title="GongZ‐Y , YeT‐H , HaoR‐R , ShiY‐X , XiongL‐Z , WangQ‐S , et al. The efficacy and safety of gabapentin in postherpetic neuralgia. Chinese Journal of Pain Medicine2008;2. ">Gong 2008</a>). We also identified one report that was a secondary analysis of a study that was already included (Calkins 2016, see <a href="./references#CD007938-bbs2-0037" title="CalkinsAM , GudinJ , GidalB , JarosMJ , KimR , ShangG . Impact of data imputation methodology on pain assessment over 24 hours in a randomized, placebo‐controlled study of gabapentin enacarbil in patients with neuropathic pain associated with postherpetic neuralgia. Pain Medicine2016;17(4):728‐36. [DOI: 10.1093/pm/pnv072] ZhangL , RainkaM , FreemanR , HardenRN , BellCF , ChenC , et al. A randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). Journal of Pain2013;14(6):590‐603. [CTG: NCT00619476; DOI: 10.1016/j.jpain.2013.01.768] ">Zhang 2013</a>), and two reports of pooled analyses of two studies that were already included (Freeman 2015 and Metha 2016, see <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>; <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>). </p> <p>One study that was previously ongoing has now completed. We could not identify a published article for this study, but we did find a synopsis with some results on the pharmaceutical company's website (<a href="./references#CD007938-bbs2-0022" title="A study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. clinicaltrials.gov/ct2/show/NCT00904202 (accessed 13 February 2017). [CTG: NCT00904202] Clinical trial results summary: a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. endo.com/home/search?k=EN3220‐009 (accessed 13 February 2017). ">NCT00904202</a>). The study satisfied our inclusion criteria and was therefore included in this review (62 participants). We could not find any updated information on the remaining three ongoing studies (<a href="./references#CD007938-bbs2-0063" title="FleckensteinJ , KramerS , HoffroggeP , ThomaS , LangPM , LehmeyerL , et al. Acupuncture in acute herpes zoster pain therapy (ACUZoster) ‐ design and protocol of a randomised controlled trial. BMC Complementary and Alternative Medicine2009;9:31. [CTG: NCT00885586; DOI: 10.1186/1472‐6882‐9‐31] ">Fleckstein 2009</a>; <a href="./references#CD007938-bbs2-0064" title="VasheghaniM (contact person) . Effect of gabapentin on heart rate variability in diabetic painful peripheral neuropathy: a double blinded randomized clinical trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201212019014N14 (accessed 13 February 2017). ">IRCT201212019014N14</a>; <a href="./references#CD007938-bbs2-0065" title="A study of the efficacy of gabapentin in neuropathic pain patients as measured by quantitative sensory testing. clinicaltrials.gov/ct2/show/NCT00674687 (accessed 13 February 2017). [NCT: NCT00674687] ">NCT00674687</a>). </p> <p>We reassessed and excluded one study that had been included in the earlier review (<a href="./references#CD007938-bbs2-0043" title="HoTW , BackonjaM , MaJ , LeibenspergerH , FromanS , PolydefkisM . Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain2009;14(1‐2):19‐24. [DOI: 10.1016/j.pain.2008.07.013] ">Ho 2009</a>). This small (18 participants) cross‐over study in small fibre sensory neuropathy used a one‐week titration period, followed by one week at the maximum dose and one week of wash‐out, then crossed over to repeat the sequence with the other treatment. We excluded it because of the very short treatment periods (only one week at a stable dose), there was some uncertainty about the dosing schedule (although the maximum dose was clearly stated), and participants could take additional gabapentin to a maximum of 1200 mg daily if they required rescue medication and paracetamol was inadequate. There was no information about the use of this additional gabapentin, or how data from participants using it were analysed. Two further studies from the previous review are in conditions not now considered neuropathic pain (<a href="./references#CD007938-bbs2-0047" title="KimosP , BiggsC , MahJ , HeoG , RashiqS , ThieNM , et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain2007;127(1‐2):151‐60. [DOI: 10.1016/j.pain.2006.08.028] ">Kimos 2007</a>; <a href="./references#CD007938-bbs2-0059" title="Van deVusseAC , Stomp‐van den BergSG , KesselsAH , WeberWE . Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. BMC Neurology2004;4:13. [DOI: 10.1186/1471‐2377‐4‐13] ">Van de Vusse 2004</a>). </p> <p><a href="#CD007938-fig-0001">Figure 1</a> illustrates the flow of studies for this update. </p> </section> <section id="CD007938-sec-0065"> <h4 class="title">Included studies</h4> <p>This update therefore includes four additional studies involving 530 participants, bringing the total for the review to 37 studies involving 5914 participants, although not all of the participants took all the study medication, and not all the participants were included in results. </p> <p>The majority of studies involved participants with PHN and PDN. Other neuropathic pain conditions studied were spinal cord injury, phantom limb pain, cancer, nerve injury pain, CRPS, HIV, and radicular leg pain. Four studies enrolled participants with a mixture of types of neuropathic pain. </p> <p>Four studies (<a href="./references#CD007938-bbs2-0017" title="IrvingG , JensenM , CramerM , WuJ , ChiangYK , TarkM , et al. Efficacy and tolerability of gastric‐retentive gabapentin for the treatment of postherpetic neuralgia: results of a double‐blind, randomized, placebo‐controlled clinical trial. Clinical Journal of Pain2009;25(3):185‐92. [DOI: 10.1097/AJP.0b013e3181934276] JensenMP , ChiangYK , WuJ . Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clinical Journal of Pain2009;25(4):286‐92. [DOI: 10.1097/AJP.0b013e318192bf87] ">Irving 2009</a>; <a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>; <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>; <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>) used a gastroretentive, extended‐release formulation of gabapentin, and four others (<a href="./references#CD007938-bbs2-0003" title="BackonjaMM , CanafaxDM , CundyKC . Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Medicine2011;12(7):1098‐108. [DOI: 10.1111/j.1526‐4637.2011.01139.x] ">Backonja 2011</a>; <a href="./references#CD007938-bbs2-0016" title="HardenRN , FreemanR , RainkaM , ZhangL , BellC , BergesA , et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine2013;14(12):1918‐32. [DOI: 10.1111/pme.12227] ">Harden 2013</a>; <a href="./references#CD007938-bbs2-0025" title="RauckR , MakumiCW , SchwartzS , GraffO , Meno‐TetangG , BellCF , et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Practice2013;13(6):485‐96. [CTG: NCT02074267; DOI: 10.1111/papr.12014] ">Rauck 2013a</a>; <a href="./references#CD007938-bbs2-0037" title="CalkinsAM , GudinJ , GidalB , JarosMJ , KimR , ShangG . Impact of data imputation methodology on pain assessment over 24 hours in a randomized, placebo‐controlled study of gabapentin enacarbil in patients with neuropathic pain associated with postherpetic neuralgia. Pain Medicine2016;17(4):728‐36. [DOI: 10.1093/pm/pnv072] ZhangL , RainkaM , FreemanR , HardenRN , BellCF , ChenC , et al. A randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). Journal of Pain2013;14(6):590‐603. [CTG: NCT00619476; DOI: 10.1016/j.jpain.2013.01.768] ">Zhang 2013</a>) used an extended‐release prodrug, gabapentin encarbil. </p> <p>Twenty‐five studies had a parallel‐group design and 12 had a cross‐over design (<a href="./references#CD007938-bbs2-0004" title="BoneM , CritchleyP , BuggyDJ . Gabapentin in postamputation phantom limb pain: a randomized, double‐blind, placebo‐controlled, cross‐over study. Regional Anesthesia and Pain Medicine2002;27(5):481‐6. [DOI: 10.1053/rapm.2002.35169] ">Bone 2002</a>; <a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>; <a href="./references#CD007938-bbs2-0011" title="GilronI , BaileyJM , TuD , HoldenRR , JacksonAC , HouldenRL . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double‐blind, randomised controlled crossover trial. Lancet2009;374(9697):1252‐61. [DOI: 10.1016/s0140‐6736(09)61081‐3] ">Gilron 2009</a>; <a href="./references#CD007938-bbs2-0013" title="GordhTE , StubhaugA , JensenTS , ArnerS , BiberB , BoivieJ , et al. Gabapentin in traumatic nerve injury pain: a randomized, double‐blind, placebo‐controlled, cross‐over, multi‐center study. Pain2008;138(2):255‐66. [DOI: 10.1016/j.pain.2007.12.011] ">Gordh 2008</a>; <a href="./references#CD007938-bbs2-0014" title="GorsonKC , SchottC , HermanR , RopperAH . Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry1999;66:251‐2. ">Gorson 1999</a>; <a href="./references#CD007938-bbs2-0016" title="HardenRN , FreemanR , RainkaM , ZhangL , BellC , BergesA , et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine2013;14(12):1918‐32. [DOI: 10.1111/pme.12227] ">Harden 2013</a>; <a href="./references#CD007938-bbs2-0018" title="LevendogluF , OgunCO , OzerbilO , OgunTC , UgurluH . Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine2004;29(7):743‐51. [DOI: 10.1097/01.BRS.0000112068.16108.3A] ">Levendoglu 2004</a>; <a href="./references#CD007938-bbs2-0020" title="MorelloCM , LeckbandSG , StonerCP , MoorhouseDF , SahagianGA . Randomized double‐blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine1999;159(16):1931‐7. [PUBMED: 10493324] ">Morello 1999</a>; <a href="./references#CD007938-bbs2-0024" title="RaoRD , MichalakJC , SloanJA , LoprinziCL , SooriGS , NikcevichDA , et al. North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy: a phase 3 randomized, double‐blind, placebo‐controlled, crossover trial (N00C3). Cancer2007;110(9):2110‐8. [CTG: NCT00027963; DOI: 10.1002/cncr.23008] ">Rao 2007</a>; <a href="./references#CD007938-bbs2-0028" title="RintalaDH , HolmesSA , CourtadeD , FiessRN , TastardLV , LoubserPG . Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation2007;88(12):1547‐60. [DOI: 10.1016/j.apmr.2007.07.038] ">Rintala 2007</a>; <a href="./references#CD007938-bbs2-0034" title="SmithDG , EhdeDM , HanleyMA , CampbellKM , JensenMP , HoffmanAJ , et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. Journal of Rehabilitation Research and Development2005;42(5):645‐54. [DOI: 10.1682/JRRD.2005.05.0082] ">Smith 2005</a>; <a href="./references#CD007938-bbs2-0035" title="TaiQ , KirshblumS , ChenB , MillisS , JohnstonM , DeLisaJA . Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double‐blind, crossover trial. Journal of Spinal Cord Medicine2002;25(2):100‐5. [PUBMED: 12137213] ">Tai 2002</a>). We used whatever data were available from the cross‐over studies, including first period or multiple periods, though there are major issues with what constitutes the ITT denominator where there are significant withdrawals. </p> <p>Parallel‐group trials were larger than cross‐over trials. The 25 parallel‐group studies involved 5298 participants (mean 204, median 162 participants, range 26 to 452), while the 12 cross‐over studies involved 621 participants (mean 48, median 40 participants, range 14 to 120). Not all studies reported the results on an ITT basis, and this was particularly the case for cross‐over studies with multiple comparisons. </p> <p>Twenty‐eight studies either described enrolment processes that were not enriched, or had no exclusion criteria that would raise the possibility of enrichment (<a href="./references#CD007938-bbs2-0170" title="StraubeS , DerryS , McQuayHJ , MooreRA . Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology2008;66(2):266‐75. [DOI: 10.1111/j.1365‐2125.2008.03200.x] ">Straube 2008</a>). Seven studies were partially enriched (<a href="./references#CD007938-bbs2-0005" title="CaraceniA , ZeccaE , BonezziC , ArcuriE , Yaya TurR , et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. Journal of Clinical Oncology2004;22(14):2909‐17. [DOI: 10.1200/JCO.2004.08.141] ">Caraceni 2004</a>; <a href="./references#CD007938-bbs2-0017" title="IrvingG , JensenM , CramerM , WuJ , ChiangYK , TarkM , et al. Efficacy and tolerability of gastric‐retentive gabapentin for the treatment of postherpetic neuralgia: results of a double‐blind, randomized, placebo‐controlled clinical trial. Clinical Journal of Pain2009;25(3):185‐92. [DOI: 10.1097/AJP.0b013e3181934276] JensenMP , ChiangYK , WuJ . Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clinical Journal of Pain2009;25(4):286‐92. [DOI: 10.1097/AJP.0b013e318192bf87] ">Irving 2009</a>; <a href="./references#CD007938-bbs2-0027" title="Study detail and analysis, Parke‐Davis 945‐295. Unpublished Report No. RR‐430‐001242000. RiceAS , MatonS , Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain2001;94(2):215‐24. [DOI: 10.1016/S0304‐3959(01)00407‐9] ">Rice 2001</a>; <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>; <a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>) or excluded participants with previous inadequate response to treatment with gabapentin or pregabalin as an exclusion criterion, which may have led to enrichment (<a href="./references#CD007938-bbs2-0007" title="CohenSP , HanlingS , BicketMC , WhiteRL , VeiziE , KuriharaC , et al. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. BMJ2015;350:h1748. [CTG: NCT01495923; DOI: 10.1136/bmj.h1748] ">Cohen 2015</a>; <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>). Two studies enriched for tolerance to gabapentin, but not response (<a href="./references#CD007938-bbs2-0003" title="BackonjaMM , CanafaxDM , CundyKC . Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Medicine2011;12(7):1098‐108. [DOI: 10.1111/j.1526‐4637.2011.01139.x] ">Backonja 2011</a>; <a href="./references#CD007938-bbs2-0016" title="HardenRN , FreemanR , RainkaM , ZhangL , BellC , BergesA , et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine2013;14(12):1918‐32. [DOI: 10.1111/pme.12227] ">Harden 2013</a>), which is probably equivalent to partial enrichment. Participants in these two studies were treated with gabapentin encarbil, a prodrug of gabapentin; these are analysed alongside the other studies, but with a view to sensitivity analysis. </p> <p>Three studies reported using baseline observation carried forward (BOCF) imputation for the primary outcome (<a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>; <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>; <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>), sometimes alongside last observation carried forward (LOCF) analyses, and one reported using BOCF imputation for the responder analyses (<a href="./references#CD007938-bbs2-0026" title="RauckR , CoffeyRJ , SchultzDM , WallaceMS , WebsterLR , McCarvilleSE , et al. Intrathecal gabapentin to treat chronic intractable noncancer pain. Anesthesiology2013;119(3):675‐86. [CTG: NCT00414466; DOI: 10.1097/ALN.0b013e3182a10fbf] ">Rauck 2013b</a>). Thirty‐one studies either made no mention of an imputation method for missing data (19) or declared use of LOCF (12). Others performed analyses on completers only (<a href="./references#CD007938-bbs2-0001" title="AtkinsonJH , SlaterMA , CapparelliEV , PatelSM , WolfsonT , GamstA , et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain2016;157(7):1499‐507. [DOI: 10.1097/j.pain.0000000000000554] ">Atkinson 2016</a> (for responder analysis); <a href="./references#CD007938-bbs2-0028" title="RintalaDH , HolmesSA , CourtadeD , FiessRN , TastardLV , LoubserPG . Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation2007;88(12):1547‐60. [DOI: 10.1016/j.apmr.2007.07.038] ">Rintala 2007</a>), and one presented results without imputation (<a href="./references#CD007938-bbs2-0024" title="RaoRD , MichalakJC , SloanJA , LoprinziCL , SooriGS , NikcevichDA , et al. North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy: a phase 3 randomized, double‐blind, placebo‐controlled, crossover trial (N00C3). Cancer2007;110(9):2110‐8. [CTG: NCT00027963; DOI: 10.1002/cncr.23008] ">Rao 2007</a>). </p> <p>Details of all eligible studies are given in the '<a href="./references#CD007938-sec-0139" title="">Characteristics of included studies</a>' table. </p> </section> <section id="CD007938-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 studies from this review. The earlier review excluded 21 studies because they were open‐label studies, were studies in chronic conditions not considered for this review, investigated related acute conditions or preventive strategies, or did not have an appropriate comparator. </p> <p>We excluded one new study because it did not have an appropriate comparator and did not appear to be blinded (<a href="./references#CD007938-bbs2-0041" title="DingY , YaoP , LanP , MaJ , WangZ , HongT , et al. Assessment of transdermal fentanyl combined with gabapentin for malignant neuropathic pain treatment. Chinese Journal of Clinical Oncology2014;41(20):1307‐11. [DOI: 10.3969/j.issn.1000‐8179.20141212] ">Ding 2014</a>). We reassessed and excluded three previously included studies, one because of its short duration, use of gabapentin as rescue medication, and unclear methods of analysis (<a href="./references#CD007938-bbs2-0043" title="HoTW , BackonjaM , MaJ , LeibenspergerH , FromanS , PolydefkisM . Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain2009;14(1‐2):19‐24. [DOI: 10.1016/j.pain.2008.07.013] ">Ho 2009</a>), and two because definitions of chronic neuropathic pain had changed, and these two were now outside the current definitions (<a href="./references#CD007938-bbs2-0047" title="KimosP , BiggsC , MahJ , HeoG , RashiqS , ThieNM , et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain2007;127(1‐2):151‐60. [DOI: 10.1016/j.pain.2006.08.028] ">Kimos 2007</a>; <a href="./references#CD007938-bbs2-0059" title="Van deVusseAC , Stomp‐van den BergSG , KesselsAH , WeberWE . Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. BMC Neurology2004;4:13. [DOI: 10.1186/1471‐2377‐4‐13] ">Van de Vusse 2004</a>). </p> </section> </section> <section id="CD007938-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessments identified that adequate sequence generation and allocation concealment were often inadequately reported. Additional risk of bias also derived from studies being small, and rarely describing how efficacy data were handled on withdrawal (<a href="#CD007938-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD007938-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007938-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD007938-sec-0068"> <h4 class="title">Allocation</h4> <p>All studies were described as randomised, but only 22 adequately described the method used to generate the random sequence. Only 19 adequately described how the sequence was concealed. We judged studies with inadequate descriptions at unclear risk, although in most cases the methods were probably adequate but not reported. </p> </section> <section id="CD007938-sec-0069"> <h4 class="title">Blinding</h4> <p>All studies were described as double‐blind (participants, who also assessed outcomes, and personnel), but six did not adequately describe the method used to achieve and maintain blinding (<a href="./references#CD007938-bbs2-0014" title="GorsonKC , SchottC , HermanR , RopperAH . Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry1999;66:251‐2. ">Gorson 1999</a>; <a href="./references#CD007938-bbs2-0016" title="HardenRN , FreemanR , RainkaM , ZhangL , BellC , BergesA , et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine2013;14(12):1918‐32. [DOI: 10.1111/pme.12227] ">Harden 2013</a>; <a href="./references#CD007938-bbs2-0019" title="MishraS , BhatnagarS , GoyalGN , RanaSP , UpadhyaSP . A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double‐blind placebo‐controlled study. American Journal of Hospice and Palliative Care2012;29(3):177‐82. [DOI: 10.1177/1049909111412539] ">Mishra 2012</a>; <a href="./references#CD007938-bbs2-0023" title="PerezHET , SanchezGF . Gabapentin therapy for diabetic neuropathic pain. Journal of Medicine2000;108:689. [DOI: 10.1016/S0002‐9343(00)00398‐3] ">Perez 2000</a>; <a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>; <a href="./references#CD007938-bbs2-0033" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. [PUBMED: 19078655] ">Simpson 2001</a>). We judged studies with inadequate descriptions at unclear risk, although in most cases the methods were probably adequate but not reported. </p> </section> <section id="CD007938-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>We judged four studies at high risk of bias because they reported only on participants who completed treatment phases (<a href="./references#CD007938-bbs2-0001" title="AtkinsonJH , SlaterMA , CapparelliEV , PatelSM , WolfsonT , GamstA , et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain2016;157(7):1499‐507. [DOI: 10.1097/j.pain.0000000000000554] ">Atkinson 2016</a>; <a href="./references#CD007938-bbs2-0028" title="RintalaDH , HolmesSA , CourtadeD , FiessRN , TastardLV , LoubserPG . Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation2007;88(12):1547‐60. [DOI: 10.1016/j.apmr.2007.07.038] ">Rintala 2007</a>), did not report groups or reasons for withdrawal and used LOCF imputation where there was 7% attrition (<a href="./references#CD007938-bbs2-0012" title="GongZ‐Y , YeT‐H , HaoR‐R , ShiY‐X , XiongL‐Z , WangQ‐S , et al. The efficacy and safety of gabapentin in postherpetic neuralgia. Chinese Journal of Pain Medicine2008;2. ">Gong 2008</a>), or did not report all expected outcomes in the results synopsis and used LOCF imputation (<a href="./references#CD007938-bbs2-0022" title="A study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. clinicaltrials.gov/ct2/show/NCT00904202 (accessed 13 February 2017). [CTG: NCT00904202] Clinical trial results summary: a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. endo.com/home/search?k=EN3220‐009 (accessed 13 February 2017). ">NCT00904202</a>). We judged five studies at low risk of bias for this domain (<a href="./references#CD007938-bbs2-0024" title="RaoRD , MichalakJC , SloanJA , LoprinziCL , SooriGS , NikcevichDA , et al. North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy: a phase 3 randomized, double‐blind, placebo‐controlled, crossover trial (N00C3). Cancer2007;110(9):2110‐8. [CTG: NCT00027963; DOI: 10.1002/cncr.23008] ">Rao 2007</a>; <a href="./references#CD007938-bbs2-0026" title="RauckR , CoffeyRJ , SchultzDM , WallaceMS , WebsterLR , McCarvilleSE , et al. Intrathecal gabapentin to treat chronic intractable noncancer pain. Anesthesiology2013;119(3):675‐86. [CTG: NCT00414466; DOI: 10.1097/ALN.0b013e3182a10fbf] ">Rauck 2013b</a>; <a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>; <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>; <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>), and the remaining 28 at unclear risk, mainly because they used LOCF imputation for early withdrawals. </p> </section> <section id="CD007938-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>We judged one study to be at low risk of bias due to study size (more than 200 participants each treatment arm; <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>), 18 at unknown risk, with between 50 and 200 participants per treatment arm, and 18 of the included studies at high risk of bias due to study size smaller than 50 participants per treatment arm. </p> </section> </section> <section id="CD007938-sec-0072"> <h3 class="title" id="CD007938-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD007938-tbl-0001"><b>Summary of findings for the main comparison</b> Gabapentin compared with placebo for postherpetic neuralgia: efficacy</a>; <a href="./full#CD007938-tbl-0002"><b>Summary of findings 2</b> Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy</a>; <a href="./full#CD007938-tbl-0003"><b>Summary of findings 3</b> Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals</a> </p> <p><a href="./appendices#CD007938-sec-0119">Appendix 7</a> contains details of withdrawals, efficacy, and adverse events in the individual studies. </p> <section id="CD007938-sec-0073"> <h4 class="title">Efficacy</h4> <p>We report efficacy results where data were available, or where there was sufficient information to justify analysis, defined as information from 200 participants or more, ideally from at least two studies. </p> <p>Analyses 1.1 to 1.5 show results for the following outcomes: at least 50% reduction in pain (<a href="./references#CD007938-fig-0010" title="">Analysis 1.1</a>; <a href="#CD007938-fig-0003">Figure 3</a>); Patient Global Impression of Change (PGIC) very much improved (<a href="./references#CD007938-fig-0011" title="">Analysis 1.2</a>; <a href="#CD007938-fig-0004">Figure 4</a>); PGIC much or very much improved (<a href="./references#CD007938-fig-0012" title="">Analysis 1.3</a>; <a href="#CD007938-fig-0005">Figure 5</a>); IMMPACT outcome of substantial improvement in pain (<a href="./references#CD007938-fig-0013" title="">Analysis 1.4</a>; <a href="#CD007938-fig-0006">Figure 6</a>); IMMPACT outcome of at least moderate improvement in pain (<a href="./references#CD007938-fig-0014" title="">Analysis 1.5</a>; <a href="#CD007938-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD007938-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.1 At least 50% pain reduction over baseline." data-id="CD007938-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.1 At least 50% pain reduction over baseline. </p> </div> </div> </div> <div class="figure" id="CD007938-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.2 Very much improved." data-id="CD007938-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.2 Very much improved. </p> </div> </div> </div> <div class="figure" id="CD007938-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.3 Much or very much improved." data-id="CD007938-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.3 Much or very much improved. </p> </div> </div> </div> <div class="figure" id="CD007938-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.4 IMMPACT outcome of substantial improvement." data-id="CD007938-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.4 IMMPACT outcome of substantial improvement. </p> </div> </div> </div> <div class="figure" id="CD007938-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.5 IMMPACT outcome of at least moderate improvement." data-id="CD007938-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.5 IMMPACT outcome of at least moderate improvement. </p> </div> </div> </div> <section id="CD007938-sec-0074"> <h5 class="title">Postherpetic neuralgia (PHN)</h5> <p>Of the 11 studies in PHN, nine (<a href="./references#CD007938-bbs2-0003" title="BackonjaMM , CanafaxDM , CundyKC . Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Medicine2011;12(7):1098‐108. [DOI: 10.1111/j.1526‐4637.2011.01139.x] ">Backonja 2011</a>; <a href="./references#CD007938-bbs2-0012" title="GongZ‐Y , YeT‐H , HaoR‐R , ShiY‐X , XiongL‐Z , WangQ‐S , et al. The efficacy and safety of gabapentin in postherpetic neuralgia. Chinese Journal of Pain Medicine2008;2. ">Gong 2008</a>; <a href="./references#CD007938-bbs2-0017" title="IrvingG , JensenM , CramerM , WuJ , ChiangYK , TarkM , et al. Efficacy and tolerability of gastric‐retentive gabapentin for the treatment of postherpetic neuralgia: results of a double‐blind, randomized, placebo‐controlled clinical trial. Clinical Journal of Pain2009;25(3):185‐92. [DOI: 10.1097/AJP.0b013e3181934276] JensenMP , ChiangYK , WuJ . Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clinical Journal of Pain2009;25(4):286‐92. [DOI: 10.1097/AJP.0b013e318192bf87] ">Irving 2009</a>; <a href="./references#CD007938-bbs2-0021" title="A Phase II, double‐blind, randomized, placebo‐controlled non‐inferiority trial of EpiCept™ NP‐1 topical cream (2% ketamine/4% amitriptyline) vs. oral gabapentin in postherpetic neuralgia (PHN). clinicaltrials.gov/ct2/show/NCT00475904 (accessed 13 February 2017). [CTG: NCT00475904] ">NCT00475904</a>; <a href="./references#CD007938-bbs2-0027" title="Study detail and analysis, Parke‐Davis 945‐295. Unpublished Report No. RR‐430‐001242000. RiceAS , MatonS , Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain2001;94(2):215‐24. [DOI: 10.1016/S0304‐3959(01)00407‐9] ">Rice 2001</a>; <a href="./references#CD007938-bbs2-0029" title="Detailed summary, study No.4, Parke‐Davis 945‐211. Unpublished Report No. RR‐995‐000701998. RowbothamM , HardenN , StaceyB , BernsteinP , Magnus‐MillerL . Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA1998;280(21):1837‐42. [DOI: 10.1001/jama.280.21.1837] ">Rowbotham 1998</a>; <a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>; <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>; <a href="./references#CD007938-bbs2-0037" title="CalkinsAM , GudinJ , GidalB , JarosMJ , KimR , ShangG . Impact of data imputation methodology on pain assessment over 24 hours in a randomized, placebo‐controlled study of gabapentin enacarbil in patients with neuropathic pain associated with postherpetic neuralgia. Pain Medicine2016;17(4):728‐36. [DOI: 10.1093/pm/pnv072] ZhangL , RainkaM , FreemanR , HardenRN , BellCF , ChenC , et al. A randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). Journal of Pain2013;14(6):590‐603. [CTG: NCT00619476; DOI: 10.1016/j.jpain.2013.01.768] ">Zhang 2013</a>) had a placebo control, and two (<a href="./references#CD007938-bbs2-0006" title="ChandraK , ShafiqN , PandhiP , GuptaS , MalhotraS . Gabapentin versus nortriptyline in post‐herpetic neuralgia patients: a randomized, double‐blind clinical trial ‐ the GONIP Trial. International Journal of Clinical Pharmacology and Therapeutics2006;44(8):358‐63. [PUBMED: 16961166] ">Chandra 2006</a>; <a href="./references#CD007938-bbs2-0016" title="HardenRN , FreemanR , RainkaM , ZhangL , BellC , BergesA , et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine2013;14(12):1918‐32. [DOI: 10.1111/pme.12227] ">Harden 2013</a>) an active control only. All nine placebo‐controlled studies had a parallel‐group design, with study duration of four to 12 weeks; daily gabapentin doses varied between 1800 mg and 3600 mg, while the dose of gabapentin encarbil was 1200 mg to 3600 mg daily. </p> <p>In seven studies reporting the outcome, at least 50% pain intensity reduction occurred in 33% of participants given gabapentin and 19% of those given placebo by the end of the study, with considerable consistency between studies (Summary of results A; <a href="#CD007938-fig-0008">Figure 8</a>). Available data on dosing regimens were too sparse to establish a dose‐response relationship. A number of outcomes consistent with IMMPACT recommendations for substantial and moderate benefit were reported in two or more placebo‐controlled studies, and the results showed gabapentin at doses of 1800 mg daily or more, or gabapentin encarbil at 1200 mg daily, to be more effective than placebo (Summary of results A). For a PGIC of much or very much improved, 39% of participants achieved this level of improvement with gabapentin and 29% with placebo. Other outcomes are reported in Summary of results A. </p> <div class="figure" id="CD007938-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Postherpetic neuralgia: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200 mg‐3600 mg daily, or placebo" data-id="CD007938-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Postherpetic neuralgia: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200 mg‐3600 mg daily, or placebo </p> </div> </div> </div> <p>Only two of these studies (<a href="./references#CD007938-bbs2-0012" title="GongZ‐Y , YeT‐H , HaoR‐R , ShiY‐X , XiongL‐Z , WangQ‐S , et al. The efficacy and safety of gabapentin in postherpetic neuralgia. Chinese Journal of Pain Medicine2008;2. ">Gong 2008</a>; <a href="./references#CD007938-bbs2-0027" title="Study detail and analysis, Parke‐Davis 945‐295. Unpublished Report No. RR‐430‐001242000. RiceAS , MatonS , Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain2001;94(2):215‐24. [DOI: 10.1016/S0304‐3959(01)00407‐9] ">Rice 2001</a>; 24% of participants) used a standard formulation of gabapentin, and removing them from the analysis did not significantly change the result. Similarly, removing the two studies using gabapentin encarbil (<a href="./references#CD007938-bbs2-0003" title="BackonjaMM , CanafaxDM , CundyKC . Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Medicine2011;12(7):1098‐108. [DOI: 10.1111/j.1526‐4637.2011.01139.x] ">Backonja 2011</a>; <a href="./references#CD007938-bbs2-0037" title="CalkinsAM , GudinJ , GidalB , JarosMJ , KimR , ShangG . Impact of data imputation methodology on pain assessment over 24 hours in a randomized, placebo‐controlled study of gabapentin enacarbil in patients with neuropathic pain associated with postherpetic neuralgia. Pain Medicine2016;17(4):728‐36. [DOI: 10.1093/pm/pnv072] ZhangL , RainkaM , FreemanR , HardenRN , BellCF , ChenC , et al. A randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). Journal of Pain2013;14(6):590‐603. [CTG: NCT00619476; DOI: 10.1016/j.jpain.2013.01.768] ">Zhang 2013</a>; 21% of participants) did not affect the result. There were insufficient data for subgroup analyses based on dose or duration of studies. </p> <p>We assessed the quality of evidence as moderate. Results were consistent between studies, but there were uncertainties and differences between dosing and dosing schedules, formulation, and imputation methods used. </p> <p><b>Summary of results A. Efficacy outcomes with gabapentin in postherpetic neuralgia (PHN)</b> </p> <p> <div class="table" id="CD007938-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Percent with outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNT<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Substantial benefit</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 50% pain intensity reduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2031</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 (1.4 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.9 (5.5 to 9.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC very much improved</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>563</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 (1.5 to 4.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (7.0 to 22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any definition of substantial benefit (at least 50% pain intensity reduction or PGIC very much improved) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2260</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.5 to 2.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.7 (5.4 to 8.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Moderate benefit</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 30% pain intensity reduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>529</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.1 to 1.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5 (4.0 to 16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC much or very much improved</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2013</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (1.2 to 1.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7 (6.9 to 16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any definition of moderate benefit (at least 25% pain intensity reduction or PGIC much or very much improved) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2260</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 (1.6 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 (4.1 to 6.0)</p> </td> </tr> </tbody> </table> </div> </p> <p>In the active controlled study involving 76 participants, gabapentin at doses of up to 2700 mg daily was compared to nortriptyline at doses of up to 150 mg daily over nine weeks. At least 50% improvement in pain over baseline using a VAS pain scale was achieved by 13/38 (34%) with gabapentin and 14/38 (37%) with nortriptyline, broadly in line with event rates in placebo‐controlled studies (<a href="./references#CD007938-bbs2-0006" title="ChandraK , ShafiqN , PandhiP , GuptaS , MalhotraS . Gabapentin versus nortriptyline in post‐herpetic neuralgia patients: a randomized, double‐blind clinical trial ‐ the GONIP Trial. International Journal of Clinical Pharmacology and Therapeutics2006;44(8):358‐63. [PUBMED: 16961166] ">Chandra 2006</a>). <a href="./references#CD007938-bbs2-0016" title="HardenRN , FreemanR , RainkaM , ZhangL , BellC , BergesA , et al. A phase 2a, randomized, crossover trial of gabapentin enacarbil for the treatment of postherpetic neuralgia in gabapentin inadequate responders. Pain Medicine2013;14(12):1918‐32. [DOI: 10.1111/pme.12227] ">Harden 2013</a> compared two dosing regimens of gabapentin encarbil in previous low dose treatment failures and found that about 13% did respond at the 50% pain reduction level. </p> </section> <section id="CD007938-sec-0075"> <h5 class="title">Painful diabetic neuropathy (PDN)</h5> <p>Seven of the nine studies in PDN were of parallel‐group design (<a href="./references#CD007938-bbs2-0002" title="Trial summary ‐ Parke Davis/Pfizer 945‐210. Unpublished report. BackonjaM , BeydounA , EdwardsKR , SchwartzSL , FonsecaV , HesM , et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA1998;280(21):1831‐6. [DOI: 10.1001/jama.280.21.1831] ">Backonja 1998</a>; <a href="./references#CD007938-bbs2-0008" title="Protocol A9451008. A 15 week, randomized, double‐blind, placebo‐controlled, parallel‐group, multi‐center study of Neurontin (gabapentin) for efficacy and quality of life in patients with painful diabetic peripheral neuropathy. PhrmaWebSynopsis ‐ Final 2 June 2005. ">CTR 945‐1008</a>; <a href="./references#CD007938-bbs2-0009" title="Protocol 945‐224. A double‐blind placebo‐controlled trial with 3 doses of gabapentin for treatment of painful diabetic peripheral neuropathy. May 29, 1998 through September 7, 1999. Unpublished. ">CTR 945‐224</a>; <a href="./references#CD007938-bbs2-0023" title="PerezHET , SanchezGF . Gabapentin therapy for diabetic neuropathic pain. Journal of Medicine2000;108:689. [DOI: 10.1016/S0002‐9343(00)00398‐3] ">Perez 2000</a>; <a href="./references#CD007938-bbs2-0025" title="RauckR , MakumiCW , SchwartzS , GraffO , Meno‐TetangG , BellCF , et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Practice2013;13(6):485‐96. [CTG: NCT02074267; DOI: 10.1111/papr.12014] ">Rauck 2013a</a>; <a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>; <a href="./references#CD007938-bbs2-0033" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. [PUBMED: 19078655] ">Simpson 2001</a>); two had a cross‐over design (<a href="./references#CD007938-bbs2-0014" title="GorsonKC , SchottC , HermanR , RopperAH . Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry1999;66:251‐2. ">Gorson 1999</a>; <a href="./references#CD007938-bbs2-0020" title="MorelloCM , LeckbandSG , StonerCP , MoorhouseDF , SahagianGA . Randomized double‐blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine1999;159(16):1931‐7. [PUBMED: 10493324] ">Morello 1999</a>). Eight had a placebo comparator, while one (<a href="./references#CD007938-bbs2-0020" title="MorelloCM , LeckbandSG , StonerCP , MoorhouseDF , SahagianGA . Randomized double‐blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine1999;159(16):1931‐7. [PUBMED: 10493324] ">Morello 1999</a>) had an active control only. Seven placebo‐controlled parallel‐group studies had a study duration between four and 14 weeks; all but one (<a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>) of seven weeks or longer. Daily gabapentin doses varied between 600 mg and 3600 mg; doses below 1200 mg were used in two studies, 900 mg daily as the only gabapentin dose in one (<a href="./references#CD007938-bbs2-0014" title="GorsonKC , SchottC , HermanR , RopperAH . Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry1999;66:251‐2. ">Gorson 1999</a>), and 600 mg daily in one arm of another (<a href="./references#CD007938-bbs2-0009" title="Protocol 945‐224. A double‐blind placebo‐controlled trial with 3 doses of gabapentin for treatment of painful diabetic peripheral neuropathy. May 29, 1998 through September 7, 1999. Unpublished. ">CTR 945‐224</a>). Gabapentin encarbil at doses of 1200 and 3600 mg daily was compared with pregabalin 300 mg daily and placebo in one study (<a href="./references#CD007938-bbs2-0025" title="RauckR , MakumiCW , SchwartzS , GraffO , Meno‐TetangG , BellCF , et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Practice2013;13(6):485‐96. [CTG: NCT02074267; DOI: 10.1111/papr.12014] ">Rauck 2013a</a>). </p> <p>At least 50% pain intensity reduction occurred in 38% of participants given gabapentin and 23% of those given placebo by the end of the study, with considerable consistency between studies (Summary of results B; <a href="#CD007938-fig-0009">Figure 9</a>). Available data on dosing regimens were too sparse to establish a dose‐response relationship. A number of outcomes consistent with IMMPACT recommendations for substantial and moderate benefit were reported in two or more placebo‐controlled studies, and the results showed gabapentin at doses of 1200 mg daily or more to be more effective than placebo (Summary of results B). For PGIC much or very much improved; 50% of participants achieved this level of improvement with gabapentin and 30% with placebo. We obtained very similar results when we omitted data from <a href="./references#CD007938-bbs2-0033" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. [PUBMED: 19078655] ">Simpson 2001</a> because of concerns one peer reviewer expressed about this study in a previous version of the review; no other efficacy outcome data were included from this study. Other outcomes are reported in Summary of results B. </p> <div class="figure" id="CD007938-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Painful diabetic neuropathy: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200‐3600 mg daily, or placebo" data-id="CD007938-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Painful diabetic neuropathy: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200‐3600 mg daily, or placebo </p> </div> </div> </div> <p>Two studies (<a href="./references#CD007938-bbs2-0025" title="RauckR , MakumiCW , SchwartzS , GraffO , Meno‐TetangG , BellCF , et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Practice2013;13(6):485‐96. [CTG: NCT02074267; DOI: 10.1111/papr.12014] ">Rauck 2013a</a>; <a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>; 35% of participants) used the gabapentin encarbil or gastroretentive formulations. Removing these from the analysis did not change the result. There were insufficient data for subgroup analyses based on dose or duration of studies. </p> <p>We assessed the quality of evidence as moderate. Results were consistent between studies, but there were uncertainties and differences between dosing and dosing schedules, formulation, and imputation methods used. </p> <p><b>Summary of results B. Efficacy outcomes with gabapentin in painful diabetic neuropathy (PDN) (1200 mg daily or greater)</b> </p> <p> <div class="table" id="CD007938-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Percent with outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNT<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Substantial benefit</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 50% pain intensity reduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1331</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7 (1.4 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6 (5.0 to 9.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC very much improved</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>408</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (1.3 to 3.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (5.5 to 35)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any definition of substantial benefit (at least 50% pain intensity reduction or PGIC very much improved) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1331</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (1.4 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.6 (5.0 to 9.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Moderate benefit</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 30% pain intensity reduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>744</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 (1.1 to 1.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4 (5.6 to 29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC much or very much improved</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>695</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (1.4 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9 (3.6 to 7.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC much or very much improved (excluding Simpson 2001)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>635</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (1.3 to 2.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 (3.7 to 8.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any definition of moderate benefit (at least 30% pain intensity reduction or PGIC much or very much improved) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1439</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.3 to 1.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.6 (4.9 to 9.9)</p> </td> </tr> </tbody> </table> </div> </p> <p>Gabapentin 600 mg daily produced lesser effects than 1200 mg and 2400 mg daily in a study that compared them (<a href="./references#CD007938-bbs2-0009" title="Protocol 945‐224. A double‐blind placebo‐controlled trial with 3 doses of gabapentin for treatment of painful diabetic peripheral neuropathy. May 29, 1998 through September 7, 1999. Unpublished. ">CTR 945‐224</a>). In one placebo‐controlled cross‐over study involving 40 randomised participants, moderate or excellent pain intensity reduction was achieved by 17/40 (43%) with gabapentin 900 mg daily over six weeks, compared with 9/40 (23%) with placebo (<a href="./references#CD007938-bbs2-0014" title="GorsonKC , SchottC , HermanR , RopperAH . Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. Journal of Neurology, Neurosurgery and Psychiatry1999;66:251‐2. ">Gorson 1999</a>). </p> <p>In one active‐controlled study involving 25 participants, gabapentin at 1800 mg daily was compared to amitriptyline 75 mg daily over six weeks. Complete or a lot of pain relief was achieved by 6/21 (29%) with gabapentin and 5/21 (24%) with amitriptyline (<a href="./references#CD007938-bbs2-0020" title="MorelloCM , LeckbandSG , StonerCP , MoorhouseDF , SahagianGA . Randomized double‐blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine1999;159(16):1931‐7. [PUBMED: 10493324] ">Morello 1999</a>). </p> </section> <section id="CD007938-sec-0076"> <h5 class="title">Mixed neuropathic pain</h5> <p>One exploratory study (<a href="./references#CD007938-bbs2-0026" title="RauckR , CoffeyRJ , SchultzDM , WallaceMS , WebsterLR , McCarvilleSE , et al. Intrathecal gabapentin to treat chronic intractable noncancer pain. Anesthesiology2013;119(3):675‐86. [CTG: NCT00414466; DOI: 10.1097/ALN.0b013e3182a10fbf] ">Rauck 2013b</a>) examined the effects of intrathecal gabapentin in participants with chronic, intractable non cancer pain, the majority (147/170; 86%) of whom were classified as having pain of neuropathic or mixed types. Three different doses (1 mg, 6 mg, and 30 mg daily) were compared with placebo. There was no significant reduction in group mean pain scores within and between groups over the 22 day treatment period. The number of participants experiencing at least 30% reduction in pain was 4/42, 4/41, 1/41, and 2/44 for the 1 mg, 6 mg, 30 mg, and placebo groups, respectively. </p> <p>Four studies examined the effects of oral gabapentin in mixed neuropathic painful conditions (<a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>; <a href="./references#CD007938-bbs2-0011" title="GilronI , BaileyJM , TuD , HoldenRR , JacksonAC , HouldenRL . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double‐blind, randomised controlled crossover trial. Lancet2009;374(9697):1252‐61. [DOI: 10.1016/s0140‐6736(09)61081‐3] ">Gilron 2009</a>; <a href="./references#CD007938-bbs2-0022" title="A study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. clinicaltrials.gov/ct2/show/NCT00904202 (accessed 13 February 2017). [CTG: NCT00904202] Clinical trial results summary: a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. endo.com/home/search?k=EN3220‐009 (accessed 13 February 2017). ">NCT00904202</a>; <a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>); two included participants with PHN and PDN (<a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>; <a href="./references#CD007938-bbs2-0011" title="GilronI , BaileyJM , TuD , HoldenRR , JacksonAC , HouldenRL . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double‐blind, randomised controlled crossover trial. Lancet2009;374(9697):1252‐61. [DOI: 10.1016/s0140‐6736(09)61081‐3] ">Gilron 2009</a>); in another the most common conditions were CRPS and PHN (<a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>); and the fourth study enrolled participants with PHN, DN, CRPS, carpel tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, and other peripheral neuropathy (proportions not reported, <a href="./references#CD007938-bbs2-0022" title="A study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. clinicaltrials.gov/ct2/show/NCT00904202 (accessed 13 February 2017). [CTG: NCT00904202] Clinical trial results summary: a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. endo.com/home/search?k=EN3220‐009 (accessed 13 February 2017). ">NCT00904202</a>). One had a parallel‐group comparison with placebo over eight weeks (<a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>), and one had a parallel‐group comparison with placebo, lidocaine patch, and gabapentin in combination with lidocaine patch over five weeks (<a href="./references#CD007938-bbs2-0022" title="A study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. clinicaltrials.gov/ct2/show/NCT00904202 (accessed 13 February 2017). [CTG: NCT00904202] Clinical trial results summary: a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. endo.com/home/search?k=EN3220‐009 (accessed 13 February 2017). ">NCT00904202</a>). The others had cross‐over designs that included placebo and morphine alone and in combination with gabapentin over five weeks (<a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>), and nortriptyline alone or in combination with gabapentin over six weeks (<a href="./references#CD007938-bbs2-0011" title="GilronI , BaileyJM , TuD , HoldenRR , JacksonAC , HouldenRL . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double‐blind, randomised controlled crossover trial. Lancet2009;374(9697):1252‐61. [DOI: 10.1016/s0140‐6736(09)61081‐3] ">Gilron 2009</a>). </p> <p>One parallel‐group comparison with placebo used gabapentin titrated to a maximum of 2400 mg daily in 305 participants (<a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>). Only for the PGIC outcome of much or very much improved was there a significant benefit of gabapentin (Summary of results C). </p> <p><b>Summary of results C. Efficacy outcomes with gabapentin in mixed neuropathic pain</b> (<a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>) </p> <p> <div class="table" id="CD007938-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Percent with outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNT<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 50% pain intensity reduction</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (0.9 to 2.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC very much improved</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0 (0.9 to 4.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PGIC much or very much improved</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2 (1.4 to 3.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> </tr> </tbody> </table> </div> </p> <p>The other parallel‐group comparison used gabapentin titrated to 1800 mg daily over one week in 62 participants (<a href="./references#CD007938-bbs2-0022" title="A study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. clinicaltrials.gov/ct2/show/NCT00904202 (accessed 13 February 2017). [CTG: NCT00904202] Clinical trial results summary: a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of lidocaine patch 5% alone, gabapentin alone, and lidocaine patch 5% and gabapentin in combination for the relief of pain in patients with diverse peripheral neuropathic pain conditions. endo.com/home/search?k=EN3220‐009 (accessed 13 February 2017). ">NCT00904202</a>), and did not report any of our specified efficacy outcomes. It did report the group mean change in pain intensity at the end of the study as 44% for gabapentin alone, 39% for lidocaine patch alone, 50% for the combination, and 26% for placebo (ITT analysis assumed). The number of participants who were satisfied or very satisfied with treatment were 65% for gabapentin alone, 69% for lidocaine patch alone, 69% for the combination, and 64% for placebo. There were no statistically significant differences between treatment groups. </p> <p>One placebo‐controlled cross‐over study (<a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>) over five weeks provided results for moderate pain relief for participants who completed a given treatment period. Gabapentin alone (target dose 3200 mg daily), morphine alone (target dose 120 mg daily), and the combination (target dose gabapentin 2400 mg plus 60 mg morphine daily) were significantly better than placebo (Summary of results D). These results were calculated from the numbers and percentages with a moderate response. The total was larger than the 57 randomised, because some participated in more than one treatment arm. </p> <p><b>Summary of results D. Efficacy outcomes with gabapentin in mixed neuropathic pain</b> (<a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>) </p> <p> <div class="table" id="CD007938-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Percent with outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least moderate pain relief</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin, morphine, of their combination</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNT<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabapentin alone</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 (1.5 to 4.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Morphine alone</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (1.9 to 5.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gabapentin plus morphine</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (1.9 to 5.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not calculated</p> </td> </tr> </tbody> </table> </div> </p> <p>The other cross‐over study compared gabapentin alone (target dose 3600 mg daily), nortriptyline (target dose 100 mg daily) and the combination (target dose 3600 mg gabapentin plus 100 mg nortriptyline daily) over six weeks (<a href="./references#CD007938-bbs2-0011" title="GilronI , BaileyJM , TuD , HoldenRR , JacksonAC , HouldenRL . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double‐blind, randomised controlled crossover trial. Lancet2009;374(9697):1252‐61. [DOI: 10.1016/s0140‐6736(09)61081‐3] ">Gilron 2009</a>). Pain intensity was significantly lower with the combination, by less than 1 point out of 10 on a numerical rating pain scale. </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> <section id="CD007938-sec-0077"> <h5 class="title">Radicular leg pain</h5> <p>One study compared gabapentin, titrated to a maximum of 3600 mg daily, with placebo over 12 weeks in 108 participants, 46 of whom had radicular pain (<a href="./references#CD007938-bbs2-0001" title="AtkinsonJH , SlaterMA , CapparelliEV , PatelSM , WolfsonT , GamstA , et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain2016;157(7):1499‐507. [DOI: 10.1097/j.pain.0000000000000554] ">Atkinson 2016</a>). Although results were not reported separately for these participants, the investigators did report that there was no difference between those with and without radicular pain. In an exploratory analysis of completers, 36% of participants in both groups reported a 30% or more decrease in pain intensity, and 26% and 29% reported a 50% or more decrease with gabapentin (34 participants) and placebo (38 participants), respectively. There was also no difference between groups for 'patient estimation of pain improvement' at the end of the study. </p> <p>Another study compared gabapentin, titrated to a target of 1800 to 3600 mg daily, with epidural steroid over three months (<a href="./references#CD007938-bbs2-0007" title="CohenSP , HanlingS , BicketMC , WhiteRL , VeiziE , KuriharaC , et al. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. BMJ2015;350:h1748. [CTG: NCT01495923; DOI: 10.1136/bmj.h1748] ">Cohen 2015</a>). The study reported only group mean decreases in average and worst leg pain at the end of treatment, which ranged from 1.6 to 2.7, with large variation within groups. There were no significant differences between the groups. </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> <section id="CD007938-sec-0078"> <h5 class="title">Spinal cord injury</h5> <p>The efficacy of gabapentin in spinal cord injury pain at maximum doses of 1800 mg or 3600 mg daily was compared with placebo in three cross‐over trials (<a href="./references#CD007938-bbs2-0018" title="LevendogluF , OgunCO , OzerbilO , OgunTC , UgurluH . Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine2004;29(7):743‐51. [DOI: 10.1097/01.BRS.0000112068.16108.3A] ">Levendoglu 2004</a>; <a href="./references#CD007938-bbs2-0028" title="RintalaDH , HolmesSA , CourtadeD , FiessRN , TastardLV , LoubserPG . Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation2007;88(12):1547‐60. [DOI: 10.1016/j.apmr.2007.07.038] ">Rintala 2007</a>; <a href="./references#CD007938-bbs2-0035" title="TaiQ , KirshblumS , ChenB , MillisS , JohnstonM , DeLisaJA . Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double‐blind, crossover trial. Journal of Spinal Cord Medicine2002;25(2):100‐5. [PUBMED: 12137213] ">Tai 2002</a>) over periods of four and eight weeks. None of the studies reported dichotomous outcomes equivalent to moderate or substantial pain relief. </p> <p>One eight‐week study randomised 20 participants to a maximum of 3600 mg gabapentin daily or placebo over eight weeks (<a href="./references#CD007938-bbs2-0018" title="LevendogluF , OgunCO , OzerbilO , OgunTC , UgurluH . Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine2004;29(7):743‐51. [DOI: 10.1097/01.BRS.0000112068.16108.3A] ">Levendoglu 2004</a>) and reported a 62% average fall in pain with gabapentin compared with a 13% fall with placebo. </p> <p>A second eight‐week study randomised 38 participants to a maximum of 3600 mg gabapentin daily, amitriptyline 150 mg daily, or placebo over eight weeks (<a href="./references#CD007938-bbs2-0028" title="RintalaDH , HolmesSA , CourtadeD , FiessRN , TastardLV , LoubserPG . Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation2007;88(12):1547‐60. [DOI: 10.1016/j.apmr.2007.07.038] ">Rintala 2007</a>). It claimed statistical superiority for amitriptyline for the 22 participants completing all three phases, and no benefit of gabapentin over placebo. </p> <p>The final study comparing gabapentin with placebo over four weeks in seven participants had no interpretable results (<a href="./references#CD007938-bbs2-0035" title="TaiQ , KirshblumS , ChenB , MillisS , JohnstonM , DeLisaJA . Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double‐blind, crossover trial. Journal of Spinal Cord Medicine2002;25(2):100‐5. [PUBMED: 12137213] ">Tai 2002</a>). </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> <section id="CD007938-sec-0079"> <h5 class="title">Nerve injury pain</h5> <p>A single cross‐over study evaluated the efficacy of gabapentin at a maximum of 2400 mg daily compared with placebo over five‐week treatment periods (<a href="./references#CD007938-bbs2-0013" title="GordhTE , StubhaugA , JensenTS , ArnerS , BiberB , BoivieJ , et al. Gabapentin in traumatic nerve injury pain: a randomized, double‐blind, placebo‐controlled, cross‐over, multi‐center study. Pain2008;138(2):255‐66. [DOI: 10.1016/j.pain.2007.12.011] ">Gordh 2008</a>). Among the 98 participants of the 120 randomised who completed both treatment periods, at least 50% pain intensity reduction was achieved by 13 (13%) with gabapentin and 9 (9%) with placebo, which did not reach statistical significance. At least 30% pain intensity reduction was achieved by 29 (29%) with gabapentin and 19 (19%) with placebo, which did not reach statistical significance. </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> <section id="CD007938-sec-0080"> <h5 class="title">Phantom limb pain</h5> <p>Two cross‐over studies evaluated the efficacy of gabapentin compared with placebo in phantom limb pain (<a href="./references#CD007938-bbs2-0004" title="BoneM , CritchleyP , BuggyDJ . Gabapentin in postamputation phantom limb pain: a randomized, double‐blind, placebo‐controlled, cross‐over study. Regional Anesthesia and Pain Medicine2002;27(5):481‐6. [DOI: 10.1053/rapm.2002.35169] ">Bone 2002</a>; <a href="./references#CD007938-bbs2-0034" title="SmithDG , EhdeDM , HanleyMA , CampbellKM , JensenMP , HoffmanAJ , et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. Journal of Rehabilitation Research and Development2005;42(5):645‐54. [DOI: 10.1682/JRRD.2005.05.0082] ">Smith 2005</a>). <a href="./references#CD007938-bbs2-0004" title="BoneM , CritchleyP , BuggyDJ . Gabapentin in postamputation phantom limb pain: a randomized, double‐blind, placebo‐controlled, cross‐over study. Regional Anesthesia and Pain Medicine2002;27(5):481‐6. [DOI: 10.1053/rapm.2002.35169] ">Bone 2002</a> randomised 19 participants to a maximum of 2400 mg gabapentin daily, or the maximum tolerated dose, with six‐week treatment periods. Using an ITT approach, weekly VAS pain scores were lower at week six only with gabapentin, but not at any other time, nor with categorical pain measures. <a href="./references#CD007938-bbs2-0034" title="SmithDG , EhdeDM , HanleyMA , CampbellKM , JensenMP , HoffmanAJ , et al. Efficacy of gabapentin in treating chronic phantom limb and residual limb pain. Journal of Rehabilitation Research and Development2005;42(5):645‐54. [DOI: 10.1682/JRRD.2005.05.0082] ">Smith 2005</a> randomised 24 participants to gabapentin titrated to a maximum daily dose of 3600 mg. A "meaningful decrease in pain" (the top of a five‐point scale) was achieved by 13 participants (54%) with gabapentin and 5 (21%) with placebo. </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> <section id="CD007938-sec-0081"> <h5 class="title">Cancer‐related neuropathic pain</h5> <p>Three studies examined gabapentin in the short term in cancer‐related neuropathic pain (<a href="./references#CD007938-bbs2-0005" title="CaraceniA , ZeccaE , BonezziC , ArcuriE , Yaya TurR , et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. Journal of Clinical Oncology2004;22(14):2909‐17. [DOI: 10.1200/JCO.2004.08.141] ">Caraceni 2004</a>; <a href="./references#CD007938-bbs2-0019" title="MishraS , BhatnagarS , GoyalGN , RanaSP , UpadhyaSP . A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double‐blind placebo‐controlled study. American Journal of Hospice and Palliative Care2012;29(3):177‐82. [DOI: 10.1177/1049909111412539] ">Mishra 2012</a>; <a href="./references#CD007938-bbs2-0024" title="RaoRD , MichalakJC , SloanJA , LoprinziCL , SooriGS , NikcevichDA , et al. North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy: a phase 3 randomized, double‐blind, placebo‐controlled, crossover trial (N00C3). Cancer2007;110(9):2110‐8. [CTG: NCT00027963; DOI: 10.1002/cncr.23008] ">Rao 2007</a>). A parallel‐group study (<a href="./references#CD007938-bbs2-0005" title="CaraceniA , ZeccaE , BonezziC , ArcuriE , Yaya TurR , et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. Journal of Clinical Oncology2004;22(14):2909‐17. [DOI: 10.1200/JCO.2004.08.141] ">Caraceni 2004</a>) randomised 121 participants to titration to a maximum of gabapentin 1800 mg daily or placebo, with 10 days of treatment. The average pain intensity was somewhat lower with gabapentin than with placebo, but the number of participants described as having pain under control was very similar with both treatments after six days, with 50% to 60% with pain under control over six to 10 days. A cross‐over study (<a href="./references#CD007938-bbs2-0024" title="RaoRD , MichalakJC , SloanJA , LoprinziCL , SooriGS , NikcevichDA , et al. North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy: a phase 3 randomized, double‐blind, placebo‐controlled, crossover trial (N00C3). Cancer2007;110(9):2110‐8. [CTG: NCT00027963; DOI: 10.1002/cncr.23008] ">Rao 2007</a>) compared gabapentin titrated to 2700 mg daily with placebo in chemotherapy‐induced neuropathic pain over three weeks. There was no significant difference between gabapentin and placebo, but the study did recruit participants both with pain or sensory loss or paraesthesia, and baseline pain scores were only about 4/10 on a numerical rating scale. The study probably lacked sensitivity to detect any difference. </p> <p>The third study compared gabapentin 1800 mg daily with pregabalin 600 mg daily and amitriptyline 100 mg daily for a total of four weeks (<a href="./references#CD007938-bbs2-0019" title="MishraS , BhatnagarS , GoyalGN , RanaSP , UpadhyaSP . A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double‐blind placebo‐controlled study. American Journal of Hospice and Palliative Care2012;29(3):177‐82. [DOI: 10.1177/1049909111412539] ">Mishra 2012</a>). No dichotomous data were reported; a decrease in pain scores in all groups in all weeks was reported, together with a morphine‐sparing effect and improvement in functional capacity. Morphine‐sparing and functional capacity were significantly better with pregabalin than the other treatments. </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> <section id="CD007938-sec-0082"> <h5 class="title">HIV‐associated sensory neuropathies</h5> <p>A single parallel‐group study compared gabapentin titrated to 2400 mg daily with placebo over four weeks in 24 participants with painful HIV‐associated neuropathies (<a href="./references#CD007938-bbs2-0015" title="HahnK , ArendtG , BraunJS , vonGiesenHJ , HusstedtIW , et al. German Neuro‐AIDS Working Group. A placebo‐controlled trial of gabapentin for painful HIV‐associated sensory neuropathies. Journal of Neurology2004;251(10):1260‐6. [DOI: 10.1007/s00415‐004‐0529‐6] ">Hahn 2004</a>). On average, pain and sleep improved substantially with both gabapentin and placebo, though the time courses differed. After four weeks, there was no difference in median pain scores, though the placebo response had an unusual time course in 11 participants. </p> <p>We assessed the quality of evidence as very low with a small number of studies, participants, and events. </p> </section> </section> <section id="CD007938-sec-0083"> <h4 class="title">Withdrawals (see Summary of results E)</h4> <p>We pooled data from participants with different types of neuropathic pain for analyses of withdrawals. </p> <section id="CD007938-sec-0084"> <h5 class="title">All‐cause withdrawals</h5> <p>Twenty‐two studies with 4617 participants reported on withdrawals for any cause, which occurred in 20% of participants with gabapentin at daily doses of 1200 mg or more, and in 19% with placebo (<a href="./references#CD007938-fig-0015" title="">Analysis 2.1</a>). The risk ratio was 1.0 (0.92 to 1.2). The NNH was not calculated. </p> </section> <section id="CD007938-sec-0085"> <h5 class="title">Adverse event withdrawals</h5> <p>Twenty‐two studies with 4346 participants reported on adverse event withdrawals, which occurred in 11% of participants with gabapentin at daily doses of 1200 mg or more, and in 8.2% with placebo (<a href="./references#CD007938-fig-0016" title="">Analysis 2.2</a>). The risk ratio was 1.4 (1.1 to 1.7), and the NNH was 30 (20 to 66). </p> </section> <section id="CD007938-sec-0086"> <h5 class="title">Lack of efficacy withdrawals</h5> <p>Fifteen studies with 3559 participants reported on lack of efficacy withdrawals, which occurred in 1.9% of participants with gabapentin at daily doses of 1200 mg or more, and in 3.3% with placebo (<a href="./references#CD007938-fig-0017" title="">Analysis 2.3</a>). The risk ratio was 0.57 (0.37 to 0.88), and the number needed to treat to prevent one withdrawal (NNTp) NNTp was 73 (41 to 360). </p> <p>We assessed the quality of evidence for withdrawals as high, based on a reasonable number of events and generally good reporting. </p> </section> </section> <section id="CD007938-sec-0087"> <h4 class="title">Adverse events (see Summary of results E)</h4> <p>We pooled data from participants with different types of neuropathic pain for analyses of adverse events. </p> <section id="CD007938-sec-0088"> <h5 class="title">Participants experiencing at least one adverse event</h5> <p>Eighteen studies with 4279 participants reported on participants experiencing at least one adverse event, which occurred in 63% of participants with gabapentin at daily doses of 1200 mg or more, and in 49% with placebo (<a href="./references#CD007938-fig-0018" title="">Analysis 3.1</a>). The risk ratio was 1.3 (1.2 to 1.4), and the NNH was 7.5 (6.1 to 9.6). We assessed the quality of evidence as moderate, based on a reasonable number of events and consistency, but limited quality of reporting adverse events. </p> </section> <section id="CD007938-sec-0089"> <h5 class="title">Serious adverse events</h5> <p>NIneteen studies reported on 3948 participants experiencing a serious adverse event, which occurred in 3.2% of participants with gabapentin at daily doses of 1200 mg or more, and in 2.8% with placebo (<a href="./references#CD007938-fig-0019" title="">Analysis 3.2</a>). The risk ratio was 1.2 (0.83 to 1.7). The NNH was not calculated. We assessed the quality of evidence as moderate due to the limited number of events. </p> </section> <section id="CD007938-sec-0090"> <h5 class="title">Particular adverse events</h5> <p>Somnolence, drowsiness, or sedation was reported as an adverse event in 20 studies with 4288 participants, and it occurred in 14% of participants with gabapentin at doses of 1200 mg daily or more, and in 5.2% with placebo (<a href="./references#CD007938-fig-0020" title="">Analysis 3.3</a>). The risk ratio was 2.8 (2.3 to 3.5), and the NNH was 11 (9.4 to 14). </p> <p>Dizziness was reported as an adverse event in 21 studies with 4739 participants, and it occurred in 19% of participants with gabapentin at doses of 1200 mg daily or more, and in 6.6% with placebo (<a href="./references#CD007938-fig-0021" title="">Analysis 3.4</a>). The risk ratio was 2.9 (2.4 to 3.4), and the NNH was 8.0 (7.0 to 9.4). </p> <p>Peripheral oedema was reported as an adverse event in 12 studies with 3325 participants, and it occurred in 6.7% of participants with gabapentin at doses of 1200 mg daily or more, and in 1.7% with placebo (<a href="./references#CD007938-fig-0022" title="">Analysis 3.5</a>). The risk ratio was 4.1 (2.7 to 6.4), and the NNH was 20 (16 to 27). </p> <p>We assessed the quality of evidence for these outcomes as moderate. While there was a reasonable number of events, definitions of adverse events and reporting was not consistent. </p> <p>Ataxia or gait disturbance was reported as an adverse event in four studies with 510 participants. It occurred in 14% of participants with gabapentin at doses of 1200 mg daily or more, and in 2.6% with placebo (<a href="./references#CD007938-fig-0023" title="">Analysis 3.6</a>). The risk ratio was 5.5 (2.5 to 12), and the NNH was 8.5 (6.1 to 14). </p> <p>We assessed the quality of evidence for ataxia as low. There was a small number of studies and events. </p> <p><b>Summary of results E: Withdrawals and adverse events with gabapentin (1200 mg daily or more) compared with placebo</b> </p> <p> <div class="table" id="CD007938-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Percent with outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNH<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal ‐ all‐cause</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4617</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.91 to 1.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal due to adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4346</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.1 to 1.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (20 to 66)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least one adverse event</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4279</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3 (1.2 to 1.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 (6.1 to 9.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse event</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3948</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.83 to 1.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence/drowsiness</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4288</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 (2.3 to 3.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (9.4 to 14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4739</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.4 to 3.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0 (7.0 to 9.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peripheral oedema</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3325</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (2.7 to 6.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (16 to 27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ataxia/gait disturbance</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>510</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (2.5 to 12)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5 (6.1 to 14)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gabapentin</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio<br/> (95% CI)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTp<br/> (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawal ‐ lack of efficacy</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3559</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57 (0.37 to 0.88)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 (41 to 360)</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD007938-sec-0091"> <h5 class="title">Death</h5> <p>Deaths were rare in these studies. Five deaths occurred in PHN studies; three with placebo: one in 231 participants (<a href="./references#CD007938-bbs2-0031" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine (Malden, Mass.)2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] SangCN , SathyanarayanaR , SweeneyM , DM‐1796 Study Investigators. Gastroretentive gabapentin (G‐GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN). Clinical Journal of Pain2013;29(4):281‐8. [DOI: 10.1097/AJP.0b013e318258993e] ">Sang 2013</a>), one in 116 (<a href="./references#CD007938-bbs2-0029" title="Detailed summary, study No.4, Parke‐Davis 945‐211. Unpublished Report No. RR‐995‐000701998. RowbothamM , HardenN , StaceyB , BernsteinP , Magnus‐MillerL . Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA1998;280(21):1837‐42. [DOI: 10.1001/jama.280.21.1837] ">Rowbotham 1998</a>) and one in 133 (<a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>); two with gabapentin: one in 223 participants (<a href="./references#CD007938-bbs2-0027" title="Study detail and analysis, Parke‐Davis 945‐295. Unpublished Report No. RR‐430‐001242000. RiceAS , MatonS , Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain2001;94(2):215‐24. [DOI: 10.1016/S0304‐3959(01)00407‐9] ">Rice 2001</a>), and one in 107 (<a href="./references#CD007938-bbs2-0017" title="IrvingG , JensenM , CramerM , WuJ , ChiangYK , TarkM , et al. Efficacy and tolerability of gastric‐retentive gabapentin for the treatment of postherpetic neuralgia: results of a double‐blind, randomized, placebo‐controlled clinical trial. Clinical Journal of Pain2009;25(3):185‐92. [DOI: 10.1097/AJP.0b013e3181934276] JensenMP , ChiangYK , WuJ . Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clinical Journal of Pain2009;25(4):286‐92. [DOI: 10.1097/AJP.0b013e318192bf87] ">Irving 2009</a>). An unpublished study (<a href="./references#CD007938-bbs2-0008" title="Protocol A9451008. A 15 week, randomized, double‐blind, placebo‐controlled, parallel‐group, multi‐center study of Neurontin (gabapentin) for efficacy and quality of life in patients with painful diabetic peripheral neuropathy. PhrmaWebSynopsis ‐ Final 2 June 2005. ">CTR 945‐1008</a>) reported two deaths: one of 200 participants treated with gabapentin, and one of 189 treated with placebo. A further study reported two deaths in 152 participants taking placebo (<a href="./references#CD007938-bbs2-0032" title="ParkeDavis/Pfizer . 945‐430‐306. Unpublished2000. SerpellMG , Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double‐blind, placebo‐controlled trial. Pain2002;99(3):557‐66. [DOI: 10.1016/S0304‐3959(02)00255‐5] ">Serpell 2002</a>). Overall, three deaths occurred with gabapentin and five with placebo. We assessed the quality of evidence as very low due to the very small number of events. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007938-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007938-sec-0092"></div> <section id="CD007938-sec-0093"> <h3 class="title" id="CD007938-sec-0093">Summary of main results</h3> <p>Gabapentin is a reasonably effective treatment for a variety of neuropathic pain conditions. It has been demonstrated to be better than placebo across all studies for IMMPACT outcomes of substantial and at least moderate improvement, producing almost identical results for all trials and those in parallel‐group studies lasting six weeks or longer. Numbers needed to treat for an additional beneficial outcome (NNTs) were between 5 and 7 for substantial and at least moderate improvement in PHN and PDN (moderate‐quality evidence). Results were consistent across the major neuropathic pain conditions tested, though gabapentin was tested only in small numbers in uncommon neuropathic pain conditions. The review concentrated on doses of gabapentin of 1200 mg daily or greater, though a wide range of fixed doses and dose titration regimens were used. </p> <p>Gabapentin was tested in nine different chronic pain conditions generally considered to be neuropathic in origin. For only three neuropathic pain conditions was there sufficient information to be confident that it worked satisfactorily, namely PHN, PDN, and mixed neuropathic pain, itself principally, though not exclusively, PHN and PDN. </p> <p>Benefit was balanced by more withdrawals due to adverse events (high‐quality evidence), and participants taking gabapentin experienced more adverse events (high‐quality evidence), including somnolence, dizziness, peripheral oedema, and gait disturbance than did those taking placebo (moderate‐quality evidence). Serious adverse events were no more common with gabapentin than placebo (moderate‐quality evidence), and death was an uncommon finding in these studies (very low‐quality evidence). </p> </section> <section id="CD007938-sec-0094"> <h3 class="title" id="CD007938-sec-0094">Overall completeness and applicability of evidence</h3> <p>Efficacy and adverse event outcomes were not consistently reported across the studies, and this limited the analyses to some extent. However, for the most important efficacy and adverse event outcomes, analyses across all conditions were mostly based on between 1000 and about 4700 participants. All the larger studies (typically those with more than 100 participants) reported some efficacy outcome equivalent to one or both of the IMMPACT outcomes of at least moderate or substantial benefit. Clearly, analysis at the level of the individual participant would facilitate a more robust estimate (<a href="./references#CD007938-bbs2-0140" title="MooreRA . What works for whom? Determining the efficacy and harm of treatments for pain. Pain2013;154(Supplement 1):S77‐S86. [DOI: 10.1016/j.pain.2013.03.024] ">Moore 2013a</a>). Such analysis can also demonstrate a link between benefit in terms of pain and benefit in other outcomes, including quality of life (<a href="./references#CD007938-bbs2-0111" title="HoffmanDL , SadoskyA , DukesEM , AlvirJ . How do changes in pain severity levels correspond to changes in health status 3 and function in patients with painful diabetic peripheral neuropathy?. Pain2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] ">Hoffman 2010</a>). </p> <p>Possible sources of bias that could have affected the results of the review included the following. </p> <p> <ul id="CD007938-list-0007"> <li> <p>Duration ‐ NNT estimates of efficacy in chronic pain studies tend to increase (get worse) with increasing duration (<a href="./references#CD007938-bbs2-0135" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] ">Moore 2010e</a>). However, limiting studies to those of six weeks or longer did not change the main efficacy outcomes, mainly because most participants were in longer‐duration studies. </p> </li> <li> <p>Outcomes may affect estimates of efficacy, but the efficacy outcomes chosen were of participants achieving the equivalent of IMMPACT‐defined moderate or substantial improvement, and it is likely that lesser benefits, such as 'any benefit' or 'any improvement', are potentially related to lesser outcomes, though this remains to be clarified. </p> </li> <li> <p>The dose of gabapentin used differed between studies, in terms of maximum allowable dose, and whether the dose was fixed, titrated to effect, or titrated up to the maximum irrespective of beneficial or adverse effects. We chose to pool data irrespective of dose, within broad limits, because it was the only practical way to deal with dose in a pooled analysis, and because of a lack of good evidence of any clear dose‐response effect for gabapentin in neuropathic pain. </p> </li> <li> <p>In some circumstances cross‐over trials have been shown to exaggerate treatment effects in comparison with parallel‐group designs (<a href="./references#CD007938-bbs2-0117" title="KhanKS , DayaS , JadadA . The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine1996;156(6):661‐6. [DOI: 10.1001/archinte.1996.00440060089011] ">Khan 1996</a>), but the extent is unclear, and it is unlikely to be the source of major bias (<a href="./references#CD007938-bbs2-0090" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). Withdrawals from cross‐over studies meant that any results were likely to be per protocol for completers rather than a true ITT analysis. Parallel‐group studies were larger than cross‐over studies, and dominated the analyses in terms of number of participants. The 25 parallel‐group studies involved 5298 participants (median 204), while the 12 cross‐over studies involved 621 participants (median 40 participants). Additionally, few cross‐over studies reported outcomes that could be used in the analyses. </p> </li> <li> <p>The absence of publication bias (unpublished trials showing no benefit of gabapentin over placebo) can never be proven. However, we can calculate the number of participants in studies of zero benefit (risk ratio of 1) required for the absolute benefit to reduce beneficial effects to a negligible amount (<a href="./references#CD007938-bbs2-0129" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). If an NNT of 10 were considered a level that would make gabapentin clinically irrelevant, then the number of participants with zero benefit would be 2448 for a moderate response and 1113 for a substantial response in PHN, and 741 for a moderate response and 887 for a substantial response in PDN. With median study size for parallel‐group studies of about 200 participants, this would require a minimum of seven unavailable studies in PHN and four in PDN. While not impossible, this seems unlikely given the paucity of new data in the last three years. </p> </li> </ul> </p> <p>There is one important unknown for most studies, namely whether the definition of response in the trials included only participants who had both an analgesic response and were able to take gabapentin. If response included an LOCF assessment of efficacy from those who discontinued, this could have affected the results (<a href="./references#CD007938-bbs2-0138" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] ">Moore 2012a</a>). LOCF tends to overestimate treatment effects when adverse event withdrawals with drug are higher than that with placebo. For gabapentin, the excess adverse withdrawal over placebo was about 3%. This is not likely to result in significant overestimation in treatment effect (<a href="./references#CD007938-bbs2-0138" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] ">Moore 2012a</a>). In a similar situation, duloxetine produced little different NNTs using LOCF and BOCF in four different chronic pain conditions (<a href="./references#CD007938-bbs2-0143" title="MooreRA , CaiN , SkljarevskiV , TölleTR . Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain2014;18(1):67‐75. [DOI: 10.1002/j.1532‐2149.2013.00341.x] ">Moore 2014b</a>). </p> <p>Another issue is how to deal with relatively short term, small, multiple cross‐over studies that intensively study participants on a daily basis (<a href="./references#CD007938-bbs2-0010" title="GilronI , BaileyJM , TuD , HoldenRR , WeaverDF , HouldenRL . Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine2005;352(13):1324‐34. [DOI: 10.1056/NEJMoa042580] ">Gilron 2005</a>; <a href="./references#CD007938-bbs2-0011" title="GilronI , BaileyJM , TuD , HoldenRR , JacksonAC , HouldenRL . Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double‐blind, randomised controlled crossover trial. Lancet2009;374(9697):1252‐61. [DOI: 10.1016/s0140‐6736(09)61081‐3] ">Gilron 2009</a>), and do not report outcomes of clinical relevance (participants with adequate pain relief), but rather average pain scores, whose relevance has been questioned because of underlying skewed distributions (<a href="./references#CD007938-bbs2-0124" title="McQuayH , CarrollD , MooreA . Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain1996;64(2):331‐5. ">McQuay 1996</a>; <a href="./references#CD007938-bbs2-0131" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , McQuayH , ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, CochranePain , Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain‐‐establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./references#CD007938-bbs2-0140" title="MooreRA . What works for whom? Determining the efficacy and harm of treatments for pain. Pain2013;154(Supplement 1):S77‐S86. [DOI: 10.1016/j.pain.2013.03.024] ">Moore 2013a</a>). This study design can provide useful and clinically relevant information, such as the relatively rapid onset of effect of therapies in neuropathic pain, or how individual patients respond to several different drugs. However, they are difficult to include in pooled analyses, and their small size and brevity come with significant potential biases. Small size has become a particular issue, with increasing association of small study size with positive bias (<a href="./references#CD007938-bbs2-0081" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartres 2013</a>; <a href="./references#CD007938-bbs2-0082" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312:623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>; <a href="./references#CD007938-bbs2-0095" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. PNAS2017;114:3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD007938-bbs2-0149" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology2017;84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>). Cochrane Reviews have received criticism for being overly confident with inadequate data (<a href="./references#CD007938-bbs2-0066" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. International Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD007938-bbs2-0074" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive‐‐Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD007938-bbs2-0162" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD007938-bbs2-0176" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane Reviews. PLoS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). </p> <p>There were almost no data for direct comparisons with other active treatments. It is questionable how important direct comparisons may be; they compare average efficacy rates between different active therapies, but individual people may respond to one drug, but not another (<a href="./references#CD007938-bbs2-0141" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690] ">Moore 2013b</a>). </p> <p>Finally, there was no way to incorporate into the review important observations on the timing and consistency of analgesia with gabapentin in neuropathic pain. In PHN, individual participant‐level pooled analyses of several large trials have demonstrated that, judged by the proportion of participants with a 1 out of 10 point pain intensity reduction, around 20 to 40 days is needed for effects to be seen (<a href="./references#CD007938-bbs2-0160" title="RauckRL , IrvingGA , WallaceMS , VanhoveGF , SweeneyM . Once‐daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double‐blind, placebo‐controlled studies. Journal of Pain and Symptom Management2013;46(2):219‐28. [DOI: 10.1016/j.jpainsymman.2012.07.011] ">Rauck 2013c</a>). Early response, defined as a 30% pain intensity reduction or greater, was predictive of response after 10 weeks, while pain intensity reduction of less than 10% at week 5 was the best early predictor of lack of response at week 10 (<a href="./references#CD007938-bbs2-0114" title="JensenMP , HsuPH , VanhoveGF . Early pain reduction can predict treatment response: results of integrated efficacy analyses of a once‐daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia. Pain Medicine2012;13(8):1059‐66. [DOI: 10.1111/j.1526‐4637.2012.01427.x.] ">Jensen 2012</a>). </p> <p>While there was considerable information about withdrawals and adverse events, rare but serious adverse events could not be addressed in these studies. We are aware that erectile dysfunction has been a cause for concern for younger men treated with antiepileptic drugs for epilepsy (<a href="./references#CD007938-bbs2-0167" title="SmaldoneM , SukkariehT , RedaA , KhanA . Epilepsy and erectile dysfunction: a review. Seizure2004;13(7):453‐9. [DOI: 10.1016/j.seizure.2003.12.006] ">Smalldone 2004</a>), and anorgasmia has been reported with gabapentin (<a href="./references#CD007938-bbs2-0154" title="PerloffMD , ThalerDE , OtisJA . Anorgasmia with gabapentin may be common in older patients. American Journal of Geriatric Pharmacotherapy2011;9(3):199‐203. [DOI: 10.1016/j.amjopharm.2011.04.007] ">Perloff 2011</a>). Adverse event reporting of erectile dysfunction or anorgasmia in these trials was sparse or not present, and the effects of gabapentin on sexual function may not be well represented. Moreover, the included studies did not address gabapentin misuse (<a href="./references#CD007938-bbs2-0094" title="EvoyKE , MorrisonMD , SakladSR . Abuse and misuse of pregabalin and gabapentin. Drugs2017;77(4):403‐26. [DOI: 10.1007/s40265‐017‐0700‐x] ">Evoy 2017</a>; <a href="./references#CD007938-bbs2-0158" title="QuinteroGC . Review about gabapentin misuse, interactions, contraindications and side effects. Journal of Experimental Pharmacology2017;9:13‐21. [10.2147/JEP.S124391. eCollection 2017] ">Quintero 2017</a>). </p> </section> <section id="CD007938-sec-0095"> <h3 class="title" id="CD007938-sec-0095">Quality of the evidence</h3> <p>The studies included in this review covered a large number of different painful conditions. The main quality issues involve reporting of outcomes of interest, particularly dichotomous outcomes equivalent to IMMPACT, appropriate analysis of data for participants who withdrew, and better reporting of adverse events. The earliest study was published in 1998, and the past decade or so has seen major changes in clinical trial reporting. The studies themselves appear to be well‐conducted, and individual participant analysis could overcome some of the shortcomings of reporting. </p> </section> <section id="CD007938-sec-0096"> <h3 class="title" id="CD007938-sec-0096">Potential biases in the review process</h3> <p>We know of no potential biases in the review process.</p> </section> <section id="CD007938-sec-0097"> <h3 class="title" id="CD007938-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>The results for neuropathic pain in this review have not changed noticeably since the last updates in 2014 and 2011. </p> <p><b>Summary of results F. Comparison of NNTs (95% CI) from previous and present reviews</b> </p> <p> <div class="table" id="CD007938-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2005 review</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>2011 update</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>2014 Update</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>2017 update</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any improvement</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IMMPACT</b> </p> <p><b>moderate benefit</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IMMPACT</b> </p> <p><b>substantial benefit</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IMMPACT</b> </p> <p><b>moderate benefit</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IMMPACT</b> </p> <p><b>substantial benefit</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IMMPACT</b> </p> <p><b>moderate benefit</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IMMPACT</b> </p> <p><b>substantial benefit</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All studies</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3 (3.5 to 5.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (4.8 to 7.2)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8 (5.6 to 8.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not calculated in this review</p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not calculated in this review</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PHN</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9 (3.0 to 5.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.5 (4.3 to 7.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.5 (5.2 to 14)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 (4.6 to 7.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8 (5.4 to 9.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (5 to 6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6 to 9)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PDN</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (2.2 to 4.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.1 (4.7 to 28)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (4.3 to 9.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6 (4.9 to 9.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9 (4.6 to 8.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (5 to 10)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (5 to 10)</p> </td> </tr> </tbody> </table> </div> </p> <section id="CD007938-sec-0098"> <h4 class="title">Other systematic reviews</h4> <p>A number of guidelines based on systematic reviews have concluded that gabapentin is helpful in neuropathic pain (<a href="./references#CD007938-bbs2-0098" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology2015;14(2):162‐73. [DOI: 10.1016/S1474‐4422(14)70251‐0] ">Finnerup 2015</a>; <a href="./references#CD007938-bbs2-0148" title="MoulinD , BoulangerA , ClarkAJ , ClarkeH , DaoT , FinleyGA , et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research &amp; Management2014;19(6):328‐35. ">Moulin 2014</a>; <a href="./references#CD007938-bbs2-0150" title="National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 13 February 2017). ">NICE 2013</a>; <a href="./references#CD007938-bbs2-0166" title="Scottish Intercollegiate Guidelines Network. SIGN Guideline 136: Management of Chronic Pain. sign.ac.uk/guidelines/fulltext/136/contents.html2013; Vol. (accessed 1 March 2017). ">SIGN 2013</a>). In PHN, a systematic review found that higher gabapentin doses may not provide greater benefit, but may increase the risk of adverse events (<a href="./references#CD007938-bbs2-0185" title="WangJ , ZhuY . Different doses of gabapentin formulations for postherpetic neuralgia: A systematical review and meta‐analysis of randomized controlled trials. Journal of Dermatology Treatment2017;28(1):65‐77. [DOI: 10.3109/09546634.2016.1163315] ">Wang 2017</a>). </p> <p>One other review has provided NNTs for gabapentin in different neuropathic pain conditions based on 50% pain relief, quoting NNTs of 4.7 and 4.3 for neuropathic pain and peripheral pain, and 4.6 for PHN and 3.9 for PDN (<a href="./references#CD007938-bbs2-0096" title="FinnerupNB , OttoM , McQuayHJ , JensenTS , SindrupSH . Algorithm for neuropathic pain treatment: an evidence based proposal. Pain2005;118(3):289‐305. [DOI: 10.1016/j.pain.2005.08.013] ">Finnerup 2005</a>). A systematic review of therapies for PHN considered gabapentin effective, with an NNT of 4.6 (<a href="./references#CD007938-bbs2-0108" title="HempenstallK , NurmikkoTJ , JohnsonRW , A'HernRP , RiceAS . Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Medicine2005;2(7):e164. [DOI: 10.1371/journal.pmed.0020164] ">Hempenstall 2005</a>). These efficacy estimates are more optimistic than NNTs for the IMMPACT substantial benefit calculated for this review, and more optimistic than NNTs calculated for the same outcome of at least 50% pain relief for PHN of 5.7 and PDN of 5.8. The use of more stringent criteria for efficacy, and availability of more information from longer duration studies has led to more conservative efficacy results. Both pregabalin and duloxetine have NNTs in the region of 5 to 6 for at least 50% pain relief over eight to 12 weeks compared with placebo in PHN and PDN (<a href="./references#CD007938-bbs2-0121" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007115.pub2] ">Lunn 2009</a>; <a href="./references#CD007938-bbs2-0130" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076] ">Moore 2009</a>; <a href="./references#CD007938-bbs2-0172" title="SultanA , GaskellH , DerryS , MooreRA . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology2008;8:29. [DOI: 10.1186/1471‐2377‐8‐29] ">Sultan 2008</a>). </p> <p>A number of other systematic reviews have examined the efficacy of gabapentin in neuropathic pain. Systematic reviews of gabapentin for neuropathic pain in spinal cord injury (<a href="./references#CD007938-bbs2-0177" title="TzellosTG , PapazisisG , AmanitiE , KouvelasD . Efficacy of pregabalin and gabapentin for neuropathic pain in spinal‐cord injury: an evidence‐based evaluation of the literature. European Journal of Clinical Pharmacology2008;64(9):851‐8. [DOI: 10.1007/s00228‐008‐0523‐5] ">Tzellos 2008</a>) and fibromyalgia (<a href="./references#CD007938-bbs2-0106" title="HaüserW , BernardyK , UceylerN , SommerC . Treatment of fibromyalgia syndrome with gabapentin and pregabalin ‐ a meta‐analysis of randomized controlled trials. Pain2009;145(1‐2):69‐81. [DOI: 10.1016/j.pain.2009.05.014] ">Hauser 2009</a>; <a href="./references#CD007938-bbs2-0178" title="TzellosTG , ToulisKA , GoulisDG , PapazisisG , ZampeliVA , VakfariA , et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta‐analysis. Journal of Clinical Pharmacology and Therapeutics2010;35(6):369‐56. [DOI: 10.1111/j.1365‐2710.2009.01144.x] ">Tzellos 2010</a>) found no more studies than those reported here. An examination of the effects of enriched enrolment found no more studies, and gave similar results for withdrawals and adverse events based on a more limited data set (<a href="./references#CD007938-bbs2-0170" title="StraubeS , DerryS , McQuayHJ , MooreRA . Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology2008;66(2):266‐75. [DOI: 10.1111/j.1365‐2125.2008.03200.x] ">Straube 2008</a>). A review comparing gabapentin and duloxetine in PDN was limited to two gabapentin studies, was statistical in nature, and restricted to average changes in some efficacy parameters (<a href="./references#CD007938-bbs2-0157" title="QuiliciS , ChancellorJ , LothgrenM , SimonD , SaidG , LeTK , et al. Meta‐analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurology2009;9:6. [DOI: 10.1186/1471‐2377‐9‐6] ">Quilici 2009</a>). The most directly relevant review was a comparison between gabapentin and tricyclic antidepressants (<a href="./references#CD007938-bbs2-0078" title="ChouR , CarsonS , ChanBK . Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post‐herpetic neuralgia: discrepancies between direct and indirect meta‐analyses of randomized controlled trials. Journal of General Internal Medicine2009;24(2):178‐88. [DOI: 10.1007/s11606‐008‐0877‐5] ">Chou 2009</a>), in which a meta‐analysis of six placebo‐controlled gabapentin studies in PHN, PDN, and mixed neuropathic pain was performed. Using a mixture of outcomes the relative benefit compared with placebo was 2.2, similar to the benefits found for the 'all studies' analysis and for analyses for PHN, PDN, and mixed neuropathic pain in this review. <a href="./references#CD007938-bbs2-0156" title="PhillipsTJ , CherryCL , CoxS , MarshallSJ , RiceAS . Pharmacological treatment of painful HIV‐associated sensory neuropathy: a systematic review and meta‐analysis of randomised controlled trials. PLOS One2010;5(12):e14433. [DOI: 10.1371/journal.pone.0014433] ">Phillips 2010</a> examined the same single study of gabapentin (<a href="./references#CD007938-bbs2-0015" title="HahnK , ArendtG , BraunJS , vonGiesenHJ , HusstedtIW , et al. German Neuro‐AIDS Working Group. A placebo‐controlled trial of gabapentin for painful HIV‐associated sensory neuropathies. Journal of Neurology2004;251(10):1260‐6. [DOI: 10.1007/s00415‐004‐0529‐6] ">Hahn 2004</a>) as part of a wider review of pharmacological interventions for HIV neuropathy and came to similar conclusions. The UK NICE guidance on pharmacological management of neuropathic pain has gabapentin as one of four drugs to try initially, with early switching if pain relief is not forthcoming (<a href="./references#CD007938-bbs2-0150" title="National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 13 February 2017). ">NICE 2013</a>). </p> <p>One further review in the public domain (<a href="./references#CD007938-bbs2-0155" title="PerryT . Neurontin ‐ expert opinion on efficacy and effectiveness for pain. industrydocumentslibrary.ucsf.edu/drug/docs/#id=fhhw0217 (accessed 13 February 2017). ">Perry 2008</a>) was performed as part of a legal case in the USA ending in 2009. <a href="./references#CD007938-bbs2-0155" title="PerryT . Neurontin ‐ expert opinion on efficacy and effectiveness for pain. industrydocumentslibrary.ucsf.edu/drug/docs/#id=fhhw0217 (accessed 13 February 2017). ">Perry 2008</a> considered similar outcomes to this review; NRS or VAS pain score was given hierarchical priority between 50% or greater reduction in pain score (higher priority) and PGIC (lower priority) mainly because it was the pre‐defined primary end point in almost all studies, and for some studies it was difficult to determine how the secondary endpoints were manipulated during post hoc changes in statistical analysis plans. The Perry conclusions are very similar to those of the present review. The likely real differences would lie in the fact that Perry excluded <a href="./references#CD007938-bbs2-0023" title="PerezHET , SanchezGF . Gabapentin therapy for diabetic neuropathic pain. Journal of Medicine2000;108:689. [DOI: 10.1016/S0002‐9343(00)00398‐3] ">Perez 2000</a> and <a href="./references#CD007938-bbs2-0033" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. [PUBMED: 19078655] ">Simpson 2001</a>, and did not have access to <a href="./references#CD007938-bbs2-0030" title="SandercockD , CramerM , BitonV , CowlesVE . A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Research and Clinical Practice2012;97(3):438‐45. [DOI: 10.1016/j.diabres.2012.03.010] SandercockD , CramerM , WuJ , ChiangYK , BitonV , HeritierM . Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double‐blind, randomized, controlled clinical trial. Diabetes Care2009;32(2):e20. [CTG: NCT00712439; DOI: 10.2337/dc08‐1450] ">Sandercock 2012</a>, <a href="./references#CD007938-bbs2-0017" title="IrvingG , JensenM , CramerM , WuJ , ChiangYK , TarkM , et al. Efficacy and tolerability of gastric‐retentive gabapentin for the treatment of postherpetic neuralgia: results of a double‐blind, randomized, placebo‐controlled clinical trial. Clinical Journal of Pain2009;25(3):185‐92. [DOI: 10.1097/AJP.0b013e3181934276] JensenMP , ChiangYK , WuJ . Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clinical Journal of Pain2009;25(4):286‐92. [DOI: 10.1097/AJP.0b013e318192bf87] ">Irving 2009</a>, and <a href="./references#CD007938-bbs2-0036" title="FreemanR , WallaceMS , SweeneyM , BackonjaMM . Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Medicine2015;16(10):2000‐11. [DOI: 10.1111/pme.12791] MehtaN , BuciorI , BujanoverS , ShahR , GulatiA . Relationship between pain relief, reduction in pain‐associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended‐release gabapentin. Health and Quality of Life Outcomes2016;14:54. [DOI: 10.1186/s12955‐016‐0456‐0] WallaceMS , IrvingG , CowlesVE . Gabapentin extended‐release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double‐blind, placebo‐controlled, multicentre study. Clinical Drug Investigation2010;30(11):765‐76. [DOI: 10.2165/11539520‐000000000‐00000] ">Wallace 2010</a>. </p> <p>Perry's conclusion on effectiveness was a clinical judgement based on balancing NNH against NNT, using the Cochrane Glossary definition of effectiveness, and presuming that inherent biases in the studies (enrichment, exclusion of many typical real world patients) implied that on balance the benefit of gabapentin use on average does not exceed the harm, which is a somewhat different issue than addressed by this Cochrane Review. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007938-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD007938-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007938-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.1 At least 50% pain reduction over baseline." data-id="CD007938-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.1 At least 50% pain reduction over baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.2 Very much improved." data-id="CD007938-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.2 Very much improved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.3 Much or very much improved." data-id="CD007938-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.3 Much or very much improved. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.4 IMMPACT outcome of substantial improvement." data-id="CD007938-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.4 IMMPACT outcome of substantial improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.5 IMMPACT outcome of at least moderate improvement." data-id="CD007938-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All placebo‐controlled studies, outcome: 1.5 IMMPACT outcome of at least moderate improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Postherpetic neuralgia: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200 mg‐3600 mg daily, or placebo" data-id="CD007938-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Postherpetic neuralgia: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200 mg‐3600 mg daily, or placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Painful diabetic neuropathy: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200‐3600 mg daily, or placebo" data-id="CD007938-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Painful diabetic neuropathy: percentage of participants achieving at least 50% pain intensity reduction (PIR) over baseline with gabapentin 1200‐3600 mg daily, or placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 1 At least 50% pain reduction over baseline." data-id="CD007938-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 1 At least 50% pain reduction over baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 2 Very much improved." data-id="CD007938-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 2 Very much improved.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 3 Much or very much improved." data-id="CD007938-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 3 Much or very much improved.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 4 IMMPACT outcome of substantial improvement." data-id="CD007938-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 4 IMMPACT outcome of substantial improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 5 IMMPACT outcome of at least moderate improvement." data-id="CD007938-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Efficacy ‐ placebo‐controlled studies, Outcome 5 IMMPACT outcome of at least moderate improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Withdrawals ‐ placebo‐controlled studies, Outcome 1 All‐cause withdrawal." data-id="CD007938-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Withdrawals ‐ placebo‐controlled studies, Outcome 1 All‐cause withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Withdrawals ‐ placebo‐controlled studies, Outcome 2 Adverse event withdrawal." data-id="CD007938-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Withdrawals ‐ placebo‐controlled studies, Outcome 2 Adverse event withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Withdrawals ‐ placebo‐controlled studies, Outcome 3 Lack of efficacy withdrawal." data-id="CD007938-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Withdrawals ‐ placebo‐controlled studies, Outcome 3 Lack of efficacy withdrawal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 1 At least one adverse event." data-id="CD007938-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 1 At least one adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 2 Serious adverse events." data-id="CD007938-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 2 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 3 Somnolence." data-id="CD007938-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 3 Somnolence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 4 Dizziness." data-id="CD007938-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 4 Dizziness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 5 Peripheral oedema." data-id="CD007938-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 5 Peripheral oedema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007938-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/urn:x-wiley:14651858:media:CD007938:CD007938-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_t/tCD007938-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Adverse events, Outcome 6 Ataxia or gait disturbance." data-id="CD007938-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Adverse events, Outcome 6 Ataxia or gait disturbance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/media/CDSR/CD007938/image_n/nCD007938-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007938-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gabapentin compared with placebo for postherpetic neuralgia: efficacy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for postherpetic neuralgia: efficacy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with postherpetic neuralgia </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> gabapentin ≥ 1800 mg daily or gabapentin encarbil 1200 mg daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with gabapentin</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR and NNT</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in pain or equivalent</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 6.9 (5.5 to 9.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>2031 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMMPACT definition ‐ any substantial pain benefit</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>170 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.8 (1.5 to 2.1)</p> <p>NNT 6.7 (5.4 to 8.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>2260 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient Global Impression of Change much or very much improved</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>390 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR1.3 (1.2 to 1.5)</p> <p>NNT 9.7 (6.9 to 16)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>2013 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMMPACT definition ‐ any at least moderate pain benefit</p> <p>(includes Gong 2008 at 25% pain relief)</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.8 (1.6 to 2.0)</p> <p>NNT 4.8 (4.1 to 6.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies</p> <p>2260 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; NNT: number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup>Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Gabapentin compared with placebo for postherpetic neuralgia: efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007938-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with peripheral diabetic neuropathy </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> ≥ 1800 mg daily or gabapentin encarbil 1200 mg daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with gabapentin</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR and NNT</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% pain intensity reduction</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 6.6 (5.0 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>1331 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any definition of substantial benefit (at least 50% pain intensity reduction or PGIC very much improved) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 6.6 (5.0 to 9.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies</p> <p>1331 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PGIC much or very much improved</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.7 (1.4 to 2.0)</p> <p>NNT 4.9 (3.6 to 7.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 studies</p> <p>695 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any definition of moderate benefit (at least 30% pain intensity reduction or PGIC much or very much improved) </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>520 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.4 (1.3 to 1.6)</p> <p>NNT 6.6 (4.9 to 9.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 studies</p> <p>1439 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded because of issues around dosing, formulation, and imputation</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials; NNT: number needed to treat for an additional beneficial outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD007938-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with neuropathic pain </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> gabapentin 1800 mg to 3600 mg daily (gabapentin encarbil 1200 mg to 3600 mg daily) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with gabapentin</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Probable outcome with placebo</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>RR and NNH</b> </p> <p><b>(95% CI)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Number of studies, participants</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="center" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing at least one adverse event</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>630 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>490 per 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.3 (1.2 to 1.4)</p> <p>NNH 7.5 (6.1 to 9.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 studies</p> <p>4279 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Many events. Unlikely new research would change this finding</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse event withdrawals</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.4 (1.1 to 1.7)</p> <p>NNH 30 (20 to 66)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 studies</p> <p>4346 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unlikely new research would change this finding</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.2 (0.83 to 1.7)</p> <p>NNH not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 studies</p> <p>3948 participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small number of events but no suggestion of difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 in max 3603 exposed</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 in max 2377 exposed</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Few events, relatively short duration for drug possibly taken over periods of years</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; NNH: number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Descriptors for levels of evidence (<a href="./references#CD007938-bbs2-0092" title="EffectivePractice , Organisation of Care(EPOC) . 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 13 February 2017). ">EPOC 2015</a>):<br/> <b>High quality:</b> this research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is low.<br/> <b>Moderate quality:</b> this research provides a good indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is moderate.<br/> <b>Low quality:</b> this research provides some indication of the likely effect. However, the likelihood that it will be substantially different<sup>†</sup> is high.<br/> <b>Very low quality:</b> this research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different<sup>†</sup> is very high. </p> <p><sup>†</sup> Substantially different: a large enough difference that it might affect a decision. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/full#CD007938-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007938-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efficacy ‐ placebo‐controlled studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At least 50% pain reduction over baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Postherpetic neuralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.43, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Painful diabetic neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.41, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Mixed neuropathic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.88, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Nerve injury pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.65, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Very much improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Postherpetic neuralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.51, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Painful diabetic neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.26, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Mixed neuropathic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [0.92, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Nerve injury pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.6 [1.39, 9.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Much or very much improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Postherpetic neuralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.16, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Painful diabetic neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.36, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Mixed neuropathic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.38, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Nerve injury pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.26, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 IMMPACT outcome of substantial improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Postherpetic neuralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.49, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Painful diabetic neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.41, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Mixed neuropathic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.88, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Nerve injury pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.65, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Phantom pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.6 [1.10, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 IMMPACT outcome of at least moderate improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Postherpetic neuralgia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.56, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Painful diabetic neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.24, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mixed neuropathic pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.49, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Nerve injury pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.92, 2.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Efficacy ‐ placebo‐controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007938-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Withdrawals ‐ placebo‐controlled studies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse event withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.14, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lack of efficacy withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.37, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Withdrawals ‐ placebo‐controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007938-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 At least one adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.22, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.83, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Somnolence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [2.27, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Dizziness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [2.40, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Peripheral oedema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.12 [2.66, 6.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ataxia or gait disturbance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.53 [2.49, 12.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007938.pub4/references#CD007938-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007938.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007938-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007938-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007938-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007938-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD007938-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007938-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD007938-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007938-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="ta#CD007938-note-0007">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007938-note-0002">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007938-note-0003">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007938\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007938\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007938\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007938\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007938\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007938.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007938.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007938.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007938.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007938.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715863906"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007938.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715863910"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007938.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d91760bd09368',t:'MTc0MDcxNTg2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 